[{"article": "\"There was no significant difference,\" Boden said.\nThe study is the first large, well-designed comparison of angioplasty to non-surgical care for patients who are not having a heart attack or in imminent danger of having one.\nThose concerns had led doctors to curtail their use of the newer devices, and the new findings are expected to have a similar effect on angioplasty overall.\nThe new study, which was funded mostly by the Department of Veterans Affairs, involved 2,287 patients at 50 centers in the United States and Canada who had chest pain or other symptoms because one or more major arteries supplying blood to the heart had clogged.\nThe researchers and others stressed that angioplasty clearly benefits patients who are in the throes of a heart attack or are at very high risk for one.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states the new study challenges routine use of a procedure \u2013 angioplasty \u2013 that has become standard care, thereby letting readers know that this procedure is\u00a0currently used and\u00a0widely available.\u00a0 ", "answer": 1}, {"article": "\u201cThey should speak with their doctor.\u201d\nOnly half of the people who originally agreed to participate in the study remained after 5 years, and it\u2019s unclear how this might affect the results, noted Chan, whose own research suggests aspirin could prevent deaths from colorectal cancer.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nAs a result, he said he suspects most people would choose to rely on regular colonoscopies to catch the disease in its early stages, rather than take a potentially risky drug for years.\nHowever, most COX-2 inhibitors ran into safety issues a few years after their approval, and now only Celebrex remains on the U.S. market.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that Celebrex is the only COX-2 inhibitor remaining on the market in the U.S., so readers should know it\u2019s available. The story could have been more clear that the drug is available only by prescription and can\u2019t be purchased over the counter.", "answer": 1}, {"article": "Natural Cycles uses a woman's body temperature and menstrual cycle data to tell her when she is fertile.\nThe app was approved as a class IIb medical device by T\u00fcv S\u00fcd, a notified body in Sweden where it is based.\nAlong with her husband and co-founder Dr Raoul Scherwitzl, Berglund created the algorithm used in the app for personal use, before deciding it was something she should share with the rest of the world.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nBut sexual health organisations are warning that being classed as a medical device does not guarantee that the app will effectively prevent pregnancy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story names the company that produces the app and links to the company\u2019s website. It also mentioned the regulatory status of the device in Sweden where the company is based.", "answer": 1}, {"article": "\u201cShe\u2019s the poster person for this test,\u201d he said.\nIn the study, even experienced radiologists at major cancer centers had a high rate of false positives, suggesting that the rate would be even higher in the real world.\n\u201cEven in these highly controlled settings, about 1 percent of the people had surgery or a part of their lung removed for something they thought was cancer and it wasn\u2019t.\u201d\n\nLow-dose CT scans expose patients to about the same radiation levels as mammograms.\nThe wording of the ad seemed to be aimed at a broad group, ranging from heavy smokers to women who had never smoked, Dr. Brawley said.\nBut because the study was stopped early, a full analysis of the harms caused by screening scans is still months away.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of CT scanners to do lung cancer screening was clear from the story.\u00a0 More importantly, though, was the question of interpreting those scans \u2013 with questions raised in this excerpt about the problems even experienced radiologists at major cancer centers had:", "answer": 1}, {"article": "Thanks to members Drs.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nThe AMSSM hopes that this information can assist healthcare professionals as they provide care for patients with osteoarthritis.\nThomas Trojian (AMSSM Past Board of Director), Susan Joy (AMSSM Foundation Board Member), Andrew Concoff and John Hatzenbuehler along with Whitney Saulsberry, PharmD and Craig Coleman, PharmD for serving on the expert writing group for this paper.\nUsing a network meta-analysis we are able to compare the multiple studies done on viscosupplementation and have found that people are more likely to show clinical improvement with viscosupplementation over placebo (saline) and intra-articular steroids.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The viscosupplementation procedure may be available at many clinics nationwide. We don\u2019t know so we are rating this Not Satisfactory. To be complete the release could have also noted that insurers place some important restrictions for payment and that\u00a0 Medicare coverage may vary among states.", "answer": 0}, {"article": "But at 25 weeks, the resolution rates were similar in the two groups: 30% of the patched group and 42% of the acupuncture group.\n''Acupuncture could potentially become an alternative treatment to occlusion [patching] therapy for ambylopia [lazy eye], the researchers write.\nU.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nThey assigned 43 children to the acupuncture group, and they received five treatments a week.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Like the competing HealthDay coverage, this story\u00a0noted that acupuncture may not be widely accepted in some areas.\u00a0But it also\u00a0never cautioned that it might be impossible to find a trained acupuncturist in many places in the U.S.\u00a0It should have pointed this out and emphasized the need to check for accreditation/licensing when choosing a practitioner.", "answer": 0}, {"article": "HPV is the most common sexually transmitted disease.\nThe FDA is not required to follow the recommendations of its outside panels of experts, but usually does.\nMerck said the drug is not intended to do that.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nA Food and Drug Administration advisory committee voted 13-0 on five separate times to endorse Merck and Co.'s Gardasil.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story treats the FDA approval as fait accompli. Although the FDA usually goes along with what the panel recommends, approval may not be automatic or occur when reported.", "answer": 0}, {"article": "Genetic factors that increase prostate cancer risk include inheritable variations in genes known as BRCA1 and BRCA2.\n\u201cAlthough these are early results, it appears that (prostate cancer) screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition,\u201d said Ros Eeles, who led a research team from Britain\u2019s Institute of Cancer Research (ICR) and Royal Marsden hospital.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nLONDON (Reuters) - Men who have a certain genetic variations that put them at higher risk of prostate cancer may benefit from regular screening for the disease, a study by British scientists found Friday.\nThe ICR-led study is aiming to find out whether screening men who have genetic variants that increase their prostate cancer risk could lead to earlier diagnosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that PSA testing is the standard screening for men, saying, \"U.S. doctors routinely recommend PSA screening in men over 50 on the assumption that early diagnosis and treatment is better than doing nothing.\"", "answer": 1}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe authors report that the dead tissue required surgical removal.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not establish whether prostatic artery embolization was currently performed in the US and if so, whether it was widely available or an option only at particular centers.", "answer": 0}, {"article": "\"She had a persistent boil on her buttocks,\" he explained.\nManuka is proving to be a moneymaker for many companies that market it online as \"nature's miracle\" and \"nature's greatest secret,\" claiming it can relieve everything from stomach ulcers to bedsores and sinus infections.\nA 250-gram jar with UMF16, which is in the midrange, sells for about $28.95 on the Internet.\nThe company, which has been developing manuka products since 2005, buys medical-grade honey from Comvita, which receives unprocessed honey from beekeepers in New Zealand.\nEven scientists who are intrigued by manuka's promise recognize that more research needs to be done.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that manuka dressings were recently approved by the FDA\u00a0and that the honey can be purchased over the internet.", "answer": 1}, {"article": "But Andrew Shao, an executive vice president at the Council for Responsible Nutrition, a trade group, said the panel was being overly cautious, especially in its recommendations about vitamin D. He said there was no convincing evidence that people were being harmed by taking supplements, and he said higher levels of vitamin D, in particular, could be beneficial.\nIt is not clear how or why the claims for high vitamin D levels started, medical experts say.\nMost vitamin D pills, he said, used to contain no more than 1,000 international units of it.\nNow it is easy to find pills, even in places like , with 5,000 international units.\nVitamin D is more complicated, the group said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of vitamin D from diet, sunlight and supplements is clear from the story.", "answer": 1}, {"article": "MORE: Losing Focus?\nBut many experts are skeptical of the alleged benefits of techniques such as transcendental meditation that claim to reduce stress by a substantial amount.\nIn the past, these benefits have been hard to test scientifically, largely because study participants who volunteered for meditation programs may have been biased to see them succeed.\nIn the latest trial to address those limitations, however, meditation does appear to have an effect on reducing heart attack, stroke and even early death from heart disease, at least among African-Americans.\nPractitioners have also made strong and essentially unsubstantiated claims about the powers of meditation, leading heart experts and scientists to be especially skeptical.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Questions like the availability of meditation trainers, insurance coverage, and the acceptability/willingness of\u00a0most patients to commit to\u00a0meditation therapy over the long-term are not addressed.", "answer": 0}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "If you piece together everything that this story said about Cymbalta, you could probably figure out that it\u2019s approved for depression and not yet approved for fibromyalgia or back pain. Of course, physicians may prescribe previously approved medications for non-approved indications. Such stories may increase use of the medicine even before the FDA has considered it for this indication \u2013 which is just fine with the company, you can be sure. \u00a0 ", "answer": 1}, {"article": "Tremors limited to the hand and forearm, for instance, might respond better than tremors that also affect the shoulder.\nMuscle weakness was the most common side effect in this study, van der Walt said.\nThere will also be the matter of cost.\nThe study\u2019s lead researcher agreed on the need for more work.\nHalf of the patients got the Botox first, the other half the placebo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of Botox was clear in the story.", "answer": 1}, {"article": "Coffee or tea?\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nWe've heard a lot about the health benefits of tea, especially green tea.\nThat's why I was so interested in a report last week in the Journal of the American...\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article discusses differences in the green tea typically available in Japan and in the United States and offers suggestion sabout where Japanese green tea can be obtained. But the suggestion that the results of the study derive only from Japanese green tea and not green tea available in the US is not justified by the study cited.", "answer": 1}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\n\u201cAnd Amgen\u2019s not a company that likes to price gouge.\u201d\n\nSchmidt said Imlygic\u2019s market potential as a standalone drug is \u201cvery, very modest.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\nAmgen will charge patients $65,000 for a course of treatment, which analysts said is in line with expectations.\nBut for the first time, scientists are poised to bring to the US market a virus that can help thwart cancer, a development that could herald a new age of viral therapies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug has been approved by the FDA, so we\u2019ll award a Satisfactory grade here. But the story could have gone further. Folks with advanced-stage melanoma do not have anywhere to turn; they will be keen to follow up on this information. A news release from Amgen indicated that the company would make the treatment available within a week, so more thorough availability information appears to have been, well, available.", "answer": 1}, {"article": "For more information on colon cancer, visit the American Cancer Society.\nThese drugs work by increasing bone thickness, thereby reducing the risk of fractures, the researchers said.\n\"Results from the only other study of bisphosphonate use and colorectal cancer, a recent large study from the United Kingdom, do not support an important protective effect,\" Jacobs noted.\nCommenting on the study, Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society, said that \"the lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing.\"\nA randomized trial is need to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both stories make it clear that these are drugs currently on the market. This story provided even more detail, saying, \u201cBisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid). These drugs work by increasing bone thickness, thereby reducing the risk of fractures, the researchers said.\u201d", "answer": 1}, {"article": "While a positive test result is highly suggestive of IBS, only 44 percent of patients with IBS tested positive, meaning that many people who test negative could in fact still have the condition.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\nBut that could finally change with the introduction of two simple new blood tests for spotting the disease.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\n\"I'm not saying the symptoms went away,\" she said, but she \"started to feel more whole.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We don\u2019t know if the tests are available, and we don\u2019t learn anything about how far away from commercialization they might be.", "answer": 0}, {"article": "\"We have the side view and the back view,\" said Kaufman.\nDr. Arie Kaufman of SUNY Stony Brook demonstrated the virtual colonoscopy for CBS New York's Dr. Max Gomez.\nThis new wave of radiology-based colonoscopy could improve those odds further.\nDoctors can then \"walk through\" the colon and explore many different angles.\n\"This will allow the physician to view 100 percent of the surface including lesions, which are hidden behind folds maybe seen on the side and back walls.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The ability of a radiologist to take a virtual stroll through a patient\u2019s bowel \u2014 i.e. the \u201cwalk-through colonoscopy\u201d touted in the article \u2014 is perhaps unique to a single site. The story doesn\u2019t establish whether or where such technology might be available outside of SUNY Stony Brook. But regardless of whether they provide the \u201cwalk-through\u201d capability described here, most academic medical centers have the capability of performing a CT colonoscopy that\u2019s the basis of this approach. Insurance coverage is a major consideration limiting its availability to the average patient", "answer": 0}, {"article": "According to the recently released 2015-2020 Dietary Guidelines for Americans, small shifts in food choices can make a big difference; including a shift from solid fats to oils, like the oil in fresh avocados.\nAs we head into American Heart Health Month (February) it's important to remind people that they have the power to help control their risk factors for developing heart disease by exercising regularly, knowing cholesterol levels and keeping them under control and maintaining a healthy weight.\nFunding for HAB comes from Hass avocado producers and importers in the United States.\nClinical studies are currently underway to investigate the relationship between avocado consumption and risk factors for heart disease, diabetes, support of weight management and healthy living.\"\nHowever, the optimal amount of avocado and frequency of use needs further evaluation along with the nutritional similarities and differences between other different MUFA sources.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that avocados are widely available so it doesn\u2019t need to be addressed in the news release.", "answer": 2}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The AP report notes that FluMist was approved in 2003. Most readers will be familiar with flu shots and capable of determining their availability.", "answer": 1}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\nBut it may be too early to call this a cure.\n\u201cThe question for me would be if there is a difference between patients who were treated with [both] immunotherapy [in the form of low doses of peanuts] and probiotics, and those who were treated with just immunotherapy.\u201d\n\nThat may have to wait for another study.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address how far along in the development process this combination therapy is, nor how far removed it may be from clinical use.", "answer": 0}, {"article": "\u2022 Ovarian cysts may occur but usually disappear.\nKyleena is available by prescription only.\nThe clinical trial had no upper or lower weight or BMI limit.\nKyleena is a trademark of Bayer.\nWHIPPANY, N.J., Sept. 19, 2016 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Kyleena\u2122 (levonorgestrel-releasing intrauterine system) 19.5 mg, a progestin-containing intrauterine system (IUS), for the prevention of pregnancy for up to five years.1 Kyleena will be available by prescription only in October 2016.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that Kyleena will be available by prescription in October 2016.", "answer": 1}, {"article": "But it was a small study, and \"it will take another year or two to get enough cases to nail down the predictive index,\" Veltri said.\nThe test is awaiting approval by the U.S. Food and Drug Administration and already is approved for use in Europe, Catalona said.\nThe Hopkins group is trying to identify other biomarkers that would improve the program's predictive value, he said.\nThe regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said.\nProstate Health Index is the name given to the test by Beckman Coulter Inc., which plans to market it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story mentioned that this test is currently \"awaiting\" FDA approval for use in the US but has already been approved for use in Europe.\nThis type of wording is misleading because it may imply that FDA approval is a done deal. \u00a0It would be better reporting to state that the product is being considered by the FDA for approval.", "answer": 1}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\nWASHINGTON\u2014An experimental drug is showing promise against an untreatable eye disease that blinds older adults \u2014 and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.\nIt turns out that nearly 6 in 10 of the study\u2019s participants carry a gene variation that makes part of the immune system go awry \u2014 a genetic flaw already known to increase the risk of getting macular degeneration in the first place.\nResults are expected later this year.\nAnd it\u2019s important for patients to know what type they have.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that the drug is not yet available, when it explains that the drug company plans to \u201copen two large-scale studies that aim to prove if the drug works. Results are expected later this year.\u201d", "answer": 1}, {"article": "\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\n\u201cI had terrible pangs of sadness and despondency.\nFriends thought Anne Schomaker was coping well with her loss, she recalled.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cThe pain just didn\u2019t go away,\u201d she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A consumer cannot tell from this story whether complicated grief therapy is widely available outside of research centers in urban areas.", "answer": 0}, {"article": "At week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\nThis study was supported by Janssen Research and Development, the manufacturer of guselkumab.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the study was a phase II clinical trial, and that a phase III trial is ongoing. In other words, the drug will not be available in the very near future. Ideally, the release would remind journalists \u2013 and the public \u2013 what a Phase II trial means and what it doesn\u2019t mean.", "answer": 1}, {"article": "\u2022 43% had at least 50% fewer arthritis symptoms, compared to 19% getting a placebo.\nThe Weinblatt study and an editorial by NIH researchers Juan Rivera, PhD, and Robert A. Colbert, MD, PhD, appear in the Sept. 30 issue of the New England Journal of Medicine.\nFor now, R788 looks very promising, the researchers report.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\nRigel funded the study, and three of the study's six authors are Rigel employees.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says up high that results from \"a pilot study\" showed that the drug\u00a0was promising in reducing the\u00a0symptoms of rheumatoid arthritis. It then says, \"Now Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial,\" making it clear that the drug is not currently available.", "answer": 1}, {"article": "A permanent artificial lens is then implanted to replace the natural lens and provide appropriate vision correction for each patient.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\nMore than 1.5 million cataract surgeries are performed annually in the U.S. One in three mostly older Americans will have the surgery at some point in their lives.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\nThat's important because ultrasound can cause collateral damage to the eye, he says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the\u00a0femtosecond laser procedure is approved by the FDA, but not widely used in the U.S.", "answer": 1}, {"article": "Moffitt is the No.\nThese data are promising, but randomized clinical trials are needed to confirm the benefit of neoadjuvant radiation therapy.\nCurrently, there are no studies that have analyzed the long-term effects of neoadjuvant radiation therapy on breast cancer patients.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nThe researchers discovered that among the breast cancer patients who tested positive for the estrogen receptor (ER) biomarker, patients who had neoadjuvant radiation therapy had a significantly lower risk of developing a second primary tumor than patients who had adjuvant radiation therapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The evidence comes from the SEER database which has been collecting data on cancer incidence for several decades, indicating that the treatment has been performed. However, the authors clearly state a need for further clinical trials to validate their hypotheses that pre-surgical radiation is a good option.", "answer": 1}, {"article": "In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\nFagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no discussion of the availability. Unlike the WebMD\u00a0story, this story did not make it clear how preliminary this research is. Instead, it used phrases such as, \"their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation\" and \"this approach could help restore sight to millions of people who are waiting for donated human corneas for transplantation.\"", "answer": 0}, {"article": "Previous studies have found that aspirin users enjoyed a lower risk of colon cancer; a trial published earlier this year concluded that people who take a daily aspirin have as much as a 46% lower risk of colon, lung and prostate cancers, compared with non-users.\nThe longer people took the drugs, and the higher the dose, the greater the anticancer benefit.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nThe drugs are thought to counter cancer growth by suppressing inflammatory pathways and stimulating tumors\u2019 ability to expand and develop blood supplies.\nAn aspirin a day could keep skin cancer away, according to a new report in the journal Cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of NSAIDs is not in question.", "answer": 2}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the story, it was clear that Crestor, the medication reported on, was currently available. \u00a0In addition, the story indicated that it did not have FDA approval for use in the way it was employed in the study.", "answer": 1}, {"article": "\"There is a tremendous lack of kidneys for transplant,\" he explained.\nOf roughly a half-million patients in the United States who were on dialysis for late-stage kidney disease in 2016, only 19,000 received kidney transplants.\nIn a study of 20 uninfected patients, researchers found that transplanting infected kidneys and then treating recipients for HCV resulted in a 100 percent cure rate.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\nAnd the average wait time for a non-infected kidney is more than two years, compared to eight months for an HCV-infected kidney.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have done a better job of explaining what steps would need to be taken to make kidneys and other organs from infected donors available. Who would have to approve of this protocol? And what further evidence is required to confirm that it\u2019s safe?\nMoreover, it\u2019s not clear how much the wait would be shortened by making HCV-infected kidneys available to patients who don\u2019t have the virus. According to data cited in an accompanying editorial, 3,562 kidneys from donors with HCV have been discarded in the U.S. since 1995; that number seems small compared to the number of people in need of a kidney.\nAlso, given a rise in HCV-infected kidneys from young donors due to the opioid crisis, it seems that efforts to curb opioid misuse might diminish the availability of those organs.", "answer": 0}, {"article": "While some teenagers want to switch from insulin injections to pump therapy to gain more flexibility in their lives, doctors said device problems such as a blocked tube can lead quickly to dangerous episodes of high blood sugar.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\nParents should be vigilant in watching their children\u2019s use of the pumps, researchers from the Food and Drug Administration wrote.\nAnd they\u2019re a growing segment of diabetes care, with $1.3 billion in annual sales worldwide, said Kelly Close, a San Francisco-based editor of a patient newsletter.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes availability in its lead sentence when it clearly states that insulin pumps are used by tens of thousands of teenagers worldwide.\u00a0 ", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that while the absorbable stent is available in Europe, Abbot will not be seeking approval for marketing in the United States until 2015.", "answer": 1}, {"article": "Cardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion.\nThe researchers hope to run a trial to show that hybrid imaging can have a positive impact on patient outcomes.\nThe shear stress information could help identify lesions that do not yet have an impact on ischemia but will in the future.\nNo additional imaging would be necessary if the results were normal.\nThe present study now documents the prognostic importance of the comprehensive assessment provided by hybrid imaging.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear how widely available the hybrid approach is. Given that the hybrid approach is really just a combination of two existing tests (a CT scan and a nuclear scan) it stands to reason that it should be available in most medical centers but the release fails to explain this.", "answer": 0}, {"article": "It doesn't stay around long enough to cause hypoglycemia,\" he said.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nThe rats got a much higher inhalation dose than humans would take, and the researchers didn't find an increase in lung cancer.\n\"They have done the required safety studies and come out clean, but it's only been tested for six months, so long-term isn't known,\" said Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation.\nCurrently, the only way to get that insulin is through injection or an insulin pump that must be inserted in a new site under the skin every few days.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes it clear that the product is not approved by the FDA for use at this time.\u00a0It needs to be pointed out that the story makes FDA approval seem like a foregone conclusion. The article is written that way. \"It will only replace meal-time insulin,\" the author writes. No, it\u00a0would\u00a0replace meal-time insulin\u00a0if\u00a0it\u2019s approved. Also, the statement that this therapy would replace meal time insulin is not supported by the evidence. \u00a0The interviewee would lead the reader to believe that meal-time insulin is dangerous, and the evidence would not support this conclusion.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the Mediterranean diet, which is composed of products readily available in most grocery stores.", "answer": 1}, {"article": "Given in the abdomen, AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among a group of healthy volunteers.\nEven this is not enough to get everyone's numbers into the safety zone, and not everyone can tolerate currently available medications.\nCardiologists were cautiously optimistic about the novel therapy.\n\"It is the early days, but the data look strong.\nFormer AHA President Dr. Ralph Sacco said that it is too early to make any predictions about what role, if any, this therapy will have in lowering cholesterol levels, but it could one day fill an important void.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this potential treatment is in an early phase of development and not yet available to the public.", "answer": 1}, {"article": "Stem cell clinics often offer expensive treatments for conditions that range from multiple sclerosis, lung and heart disease, to cosmetic treatments, such as facelifts.\nGiven that the stem cell-treated knee was no better than the control-treated knee \u2014 both were significantly better than before the study began \u2014 the researchers say the stem cells\u2019 effectiveness remains somewhat uninterpretable.\nThey are only able to conclude the procedure is safe to undergo as an option for knee pain, but they cannot yet recommend it for routine arthritis care.\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release prominently notes the wide availability of regenerative medicine clinics and their offerings of BMAC for knees and other arthritic joints. And it makes clear that the results of this new small trial cannot underpin recommendations for its \u201croutine\u201d use. The release would have been stronger if it had explained what \u201cnon routine\u201d use means in the context of the study\u2019s findings.", "answer": 1}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nStill others, like Dr. Glick, are starting to tell women with estrogen-fed cancers that although they still need chemotherapy, they may not need the most intense treatment.\nAnd for good reason, many cancer researchers say: a series of large studies has shown that chemotherapy saves lives and that newer and more aggressive regimens are improvements over older ones.\nAnd the recent data indicating that some women can skip chemotherapy are based on an after-the-fact analysis of selected clinical trials.\nNow Dr. Berry, the M. D. Anderson statistician, and a group of leading cancer researchers have found that the chemotherapy benefits in those clinical trials were concentrated almost exclusively in women whose cancers were impervious to estrogen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that adjuvant chemotherapy is widely used in breast cancer treatment. Established clinical guidelines based on current evidence suggest that most women with invasive breast cancer and lymph node involvement should not forgo chemotherapy. Physicians are cautious about changes in practice at this time, but some are already presenting the new data to patients and suggesting that chemotherapy may be tailored to a patient\u2019s type of breast cancer. ", "answer": 1}, {"article": "\u201cOur lab is on an island in the South.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\nThis information is in the early stages of transforming the category of after-sun care\u2014a category traditionally limited to aloe vera-laden moisturizers and gels that lowered the temperature of sun-parched skin but not much else.\n(She\u2019s also called on Terrence Collins, the Teresa Heinz Professor of Green Chemistry at Carnegie Mellon University as a consultant to formulate her line.)\nNot everyone is convinced of the effectiveness of after-sun care.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the products mentioned in the story are currently available. The photo caption includes links to manufacturer web sites.", "answer": 1}, {"article": "But on Oct. 23, the F.D.A.\nAnecdotes like Ms. Gurno\u2019s aside, the efficacy of peramivir is still in question, according to the government.\nRight now, Dr. Lurie said, peramivir is the only drug that can be used intravenously so the government had to pay a high price.\nThe government is paying an average of only $450 a course for those other drugs \u2014 only one-fifth of what it is paying for peramivir.\nBut in the United States, BioCryst plans to try to win approval for treatment only of hospitalized patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story makes very clear that peramivir is experimental and is being offered only because some patients cannot take or aren\u2019t helped by approved antiviral drugs.", "answer": 1}, {"article": "Nonetheless, the doctors were pleased when M.R.I.\nWith the best treatment, the median survival time is about 15 months.\nIts best results have been in people with a rare type of brain tumor called a primary central nervous system lymphoma.\nTheir study involves a technique first developed about 30 years ago, which uses mannitol to open the blood-brain barrier temporarily to get chemotherapy into the brain.\nscans of the first few patients showed that the treatment seemed to erase any sign of recurring glioblastomas.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes very clear that the approach described is experimental and not clinically available. It is the subject of a Phase I trial of 30 patients.\u00a0 ", "answer": 1}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\u2022 Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room.\nUTSW is currently the only accredited site in Texas at which this spacer gel can be used.\n\"SBRT is both more convenient and has increased potency.\"\nIt is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.\nTo reduce the side effects associated with SBRT, current clinical trials at UTSW are using a unique and biodegradable rectal spacer gel to protect the rectum.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release hints that SBRT is available at the study location but does not provide readers with any other indication about its availability in other regions. We do know that SBRT is widely available at other academic medical centers and has been in use for more than a decade. It is also sometimes marketed as the \u201cCyberKnife\u201d at private medical facilities.", "answer": 0}, {"article": "Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.\nSuch an immune mechanism has never been reported before.\nCapsule co-inventor, RMIT's Dr Kyle Berean, said the second human trials have revealed information about gas production in the gut previously masked when measured indirectly through the breath.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\nThe vitamin pill-sized capsule, currently being commercialised by Atmo Biosciences, provides real time detection and measurement of hydrogen, carbon dioxides and oxygen in the gut.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s implied the capsule is in development and not commercially available at this time.", "answer": 1}, {"article": "In general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle.\nThey didn\u2019t include patients who made over-the-counter purchases of the medicines.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\nEarlier studies had suggested that aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may help protect against colorectal cancer, but it wasn\u2019t clear how much had to be taken, and for how long, to achieve those benefits.\nThe study had several limitations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The ubiquity of low-dose aspirin is so well known that it did not need to be mentioned.", "answer": 1}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\nWhile alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.\nThere\u2019s a good explanation for that: While the research shows that 12-step treatment can be as effective as professional treatment modalities like cognitive behavioral therapy, the research also shows that the 12 steps don\u2019t work for everyone.\nBy showing that there really might be other effective options out there, the research provides hope that there may be a better \u2014 or at least more complete \u2014 solution out there for alcohol addiction.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story thoroughly addresses the gulf in availability between 12-step programs and alternative approaches.\nMost treatment facilities in America are, according to the\u00a0survey data and research, at least partly based on the 12 steps \u2014 making it the\u00a0only option for many people. While alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.", "answer": 1}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nHelen Rippon, head of research management at Britain's Prostate Cancer Charity, said the benefits of hormone therapy ultimately outweighed the increased risk of heart problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story points out that hormone therapy is commonly given to men with prostate cancer.\n However, the lead sentences mislead readers by describing hormone therapy as a single treatment, rather than a collection of different treatments. The distinction is particularly important because this study and others indicate that different hormonal therapy techniques may be associated with different risks of heart disease. ", "answer": 1}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers would have benefited from some information about the availability of weight loss surgery in the U.S. Is the newer sleeve gastrectomy procedure available everywhere across the country? What are the criteria for insurance coverage?", "answer": 0}, {"article": "Women aged 70 to 75 had the greatest risk reduction, reducing the risk of dying from breast cancer by 84 percent.\nThe greater risk reduction in women aged 70 to 75, Otto said, is probably a result of the long-term good effects of screening participation in the earlier target age group, 50 to 69, before the upper age limit for screening was extended in the Netherlands from 69 to 75.\nThe study, however, has some limitations, Bernik noted.\nOtto's study only looked at women aged 49 and older.\n\"This study focuses on survival.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The study was in the Netherlands, which has a national screening program.\n\u00a0", "answer": 2}, {"article": "Professor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\nIn no study was serious or life-threatening bleeding reported.\"\nThis is not the only significant study Professor Elwood led research examining ways to improve peoples' health.\nThat's why we specifically looked at the available evidence of bleeding and we wrote to all authors asking for further data.\nThe study was the longest of its kind to probe the influence of environmental factors in chronic disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability but we know aspirin is available in pretty much any convenience store on Earth. We\u2019ll rate this \u201cnot applicable.\u201d", "answer": 2}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that these devices are available and from which manufacturers.", "answer": 1}, {"article": "Please see the study for full details.\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\n\"This study should encourage physicians to use their osteopathic techniques when treating older patients with pneumonia.\"\n\"Osteopathic manipulative therapy was developed in the pre-antibiotic era specifically for the management of pneumonia.\nWhile antibiotic therapy is the current standard of care, the emergence of resistant bacteria is a global threat and provides an incentive to explore adjunct treatments that can improve their efficacy,\" said James Bailey, DO, assistant professor in physical medicine and rehabilitation at Rowan University School of Osteopathic Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that osteopathic manipulative therapy is established practice for osteopaths and presumably could be available in hospitals more broadly.\nBut we thought the availability of the procedure could have been made much more clear. How would a patient know if their provider was an osteopath? What would it take to implement this more broadly? Could non-osteopaths be taught to do this? Could non-physicians? It\u2019s implied that osteopathic physicians who take care of patients hospitalized with pneumonia could do this. But do patients really know whether their physician is an osteopath?", "answer": 0}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nLarger studies in many more patients are needed before the drug will be available, though, she says.\nThere was even a hint that the drug helped to slow the decline in functioning.\nThe results really became clear when the researchers looked only at those patients with mild, early-stage disease.\n\"But the study offers evidence that targeting beta-amyloid can benefit patients,\" she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the drug is still being tested.", "answer": 1}, {"article": "\"They got it completely wrong,\" he said.\nWhy, he asks, should patients undergo two tests when one is sufficient?\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\nThe prospects for significant expansion of the procedure, which is covered by a growing number of insurance companies, have collided with a large and unexpected roadblock.\nWhen Eric Rowe turned 50, the question was not whether the Washington lawyer would be screened for colon cancer, but how.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly virtual colonoscopy is available. The story could have described how widely available the procedure is \u2013 for example, is it still only limited to large, academic or urban medical centers?", "answer": 1}, {"article": "The law, the first in any state, takes effect Jan. 1.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nThat translates into \u201cabout 5,600 individuals developing a radiation-induced cancer in the future,\u201d the study said.\nThe Texas law will require insurance companies pay $200 of the bill for patients to get the test every five years.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story says that the CT scanners used for this test are \u201call over the city\u201d and included an estimate that in 2008 about 200,000 people around the country were scanned for calcium buildups in their coronary arteries.", "answer": 1}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\nThat's the same level of efficacy seen with antipsychotic medications, note study researcher G. Paul Amminger, MD, of the University of Vienna, Austria, and colleagues.\nIt's also not clear how fish oil might prevent psychiatric disorders.\nFish oil pills have no serious side effects.\nThe study suggests that to prevent one case of psychosis, four high-risk young people must be treated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fish oil pills sold as dietary supplements are widely available; however, supplement formulations can vary widely and some may only be available with a prescription. More information on the specific formulation used in the study, as well as the dosage would have been useful. \n\u00a0", "answer": 1}, {"article": ".\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThe company's shares rose 24 cents to close at $3.84.\nThe company plans to announce results of the first Phase 3 clinical trial of the drug at the end of March, Chief Executive Jack Lief said.\nIf approved, lorcaserin would be Arena's first marketable product.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that it was reporting on the results of a recent clinical trial and that a request for FDA approval had not yet been made, from which the reader could conclude that the drug is currently not available.", "answer": 1}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nThe study was funded by Pfizer Inc and the National Institutes of Health (5P30 CA16520-25).\nThese tools can help to individualize patient therapy going forward.\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nThe lower their neutrophil count, the more vulnerable patients are to infectious diseases.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of whether this drug is currently approved or how widely this drug is used.", "answer": 0}, {"article": "Surgery also typically involves significant breast tissue damage and disfigurement due to large incisions and removal of sizable breast mass.\nWe are confident that the ICE3 trial can prove certain women can be successfully treated less aggressively than in the past.\nThe ICE3 trial is recruiting and following women aged 65 years and older diagnosed with certain tumor sub-types and measuring less than 1.5 centimeters in diameter.\nThe ICE3 trial, which began patient enrollment in October 2014, will significantly expand data on the technique as a treatment for breast cancer.\nAs a market leader in cryoablation treatment of breast disease, IceCure will utilize its resources to provide clinical and technological support to sites in the cancer trial.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told ICE3 is currently in clinical trials for treating breast cancer and is only available at 20 US sites, at least two of which are named in the release.", "answer": 1}, {"article": "on Sept. 2.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\nIt says it will give the drug free to uninsured patients who cannot pay for it any other way.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that Folotyn is not currently available but that the manufacturer plans to market the drug in January.", "answer": 1}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nThe cap is not yet available to consumers, although the lead researcher, Dr. Eric Nofzinger, has plans to bring it to market, Buysse said.\nBuysee said there shouldn't be any safety issues.\nBecause this study was extremely small and presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal and confirmed in larger studies.\nMedications can help, although many people complain of side effects, Kohler said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the approach is experimental and not yet available to consumers.", "answer": 1}, {"article": "Both doctors improved their detection rates of potentially dangerous adenomatous polyps when they listened to music compared with their pre-study (\"baseline\") rates, the investigators found.\nIn their small study, two doctors performed endoscopies either while listening to Mozart or with no music at all.\nDetection rates for the first doctor were about 67 percent while listening to music and 30 percent with no music.\nWhile this is a small study, the results highlight how thinking outside the box -- in this case using Mozart -- to improve adenoma detection rates can potentially prove valuable to physicians and patients.\"\nThis was up from a baseline detection rate of 21 percent before the study began.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There\u2019s no question about the ability of anyone to listen to any of kind of music while doing colonoscopies.", "answer": 2}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nThe company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\nShe was getting her MBA and I'd gotten my engineering degree from there.\nWe had this shared experience; Shireen has several food allergies and I also have several food intolerances.\n\"So we do not need FDA clearance for the device because we are not using it to diagnose or manage disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the product is a bit vague, but it\u2019s there.\u00a0The timeline of \u201cthe middle of next year\u201d is provided for availability.", "answer": 1}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nInstead, Kathiresan can calculate risk scores for those five diseases \u2014 eventually maybe more \u2014 simply by reanalyzing the kind of raw data people receive after sending a cheek swab to companies like 23andMe.\nKathiresan and co-author Dr. Amit Khera, a Mass General cardiologist, are co-inventors on a patent application for the system.\nThe scoring system can also predict an increased risk of Type 2 diabetes, inflammatory bowel disease, breast cancer and an irregular heartbeat called atrial fibrillation, the team reported in the journal Nature Genetics \u2014 noting that next steps include learning what might likewise lower those risks.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One of the researchers suggests that \u201cin five years, each person will know this risk number, this \u2018polygenic risk score,\u2019 similar to the way each person knows his or her cholesterol,\u201d making clear that the technology isn\u2019t available to patients now.\u00a0 Moreover, the story adds that he \u201chopes to open a website where people can send in such data to learn their heart risk,\u201d something that clearly doesn\u2019t exist yet.", "answer": 1}, {"article": "This didn't stop MS.\"\n\n\"But, this is extremely hopeful research,\" he added.\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\nThe team added that the new medication appears to tackle MS by a different type of mechanism than other available options, and apparently works by curtailing the onset of permanent tissue damage while limiting acute inflammation.\nThe study found that to date, the new drug appears to be both safe and well-tolerated.\nLaquinimod was not, however, tested against currently existing treatment alternatives, the authors stressed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains early that the drug is currently not available and also that it is only one of many options by saying, \u201cIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\u201d", "answer": 1}, {"article": "Fat tissue has been linked to higher levels of damaging metabolic stress compounds, so losing weight and becoming more fit may create more hospitable conditions for sperm and improve its quality and volume.\nNow, researchers publishing in the journal have found that another lifestyle change\u2014exercise\u2014may also help improve sperm quality.\nThere are already plenty of reasons to exercise, and now better quality sperm is one more worth noting.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\nWhile it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Exercise \u2014 in this case, running \u2014 is clearly a readily available activity for most individuals.\u00a0 They simply have to decide to do it. Some explanation of the availability of effective HIIT training could have been added, though.", "answer": 2}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\nBut the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes.\nWHO: Jerome Fleg, MD and Yves Rosenberg, MD, M.P.H., Division of Cardiovascular Sciences, NHLBI, NIH, are available to comment on the findings and implications of this research.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the drug is not clear in the release. Although this is a previously approved drug that can be prescribed by doctors, some insurers may not cover it or cover it with higher co-payments. This could have been mentioned in the release. ", "answer": 0}, {"article": ".\nWhile the researchers state their findings to date indicate cannabis may decrease dependence on prescription medicines, including opioids, more evidence-based data from this special, aging population is imperative.\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\n\"While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,\" says Prof. Victor Novack, M.D., a professor of medicine in the BGU Faculty of Health Sciences (FOHS), and head of the Soroka Cannabis Clinical Research Institute.\nThis older population represents a growing segment of medical cannabis users, ranging from approximately seven percent to more than 33 percent, depending on the country.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not address which countries (other than Israel) or US states have legalized medical marijuana. Availability depends very much on where the patient lives.", "answer": 0}, {"article": "When the researchers factored in other diet habits, exercise levels and major risk factors for stroke \u2014 like high blood pressure and diabetes \u2014 heavy olive oil use was tied to 41 percent reduction in the odds of stroke.\nOlive oil is a key ingredient in the so-called Mediterranean diet.\nOlive oil is one part of the Mediterranean diet that has been tied to heart benefits.\nWhat\u2019s needed, he said, are clinical trials where people are randomly assigned to use olive oil or not, then followed over time to see who suffers a stroke.\nAnd after they did, olive oil was still linked to a lower stroke risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of olive oil is not in question.", "answer": 2}, {"article": "Dr. Carroll's co-authors are Eric C. Larsen at Maine Children's Cancer Program, Scarborough, ME; Meenakshi Devidas and Si Chen at the University of Florida; Wanda L. Salzer at the U.S. Army Medical Research and Materiel Command, Fort Detrick, MD; James B. Nachman at the University of Chicago; Elizabeth A. Raetz at the University of Utah; Mignon L. Loh at the Benioff Children's Hospital and the University of California, San Francisco; Leonard A. Mattano Jr. at HARP Pharma Consulting; Catherine Cole at Princess Margaret Hospital for Children and University of Western Australia; Alisa Eicher at Doernbecher Children's Hospital, Portland, OR; Maureen Haugan at Ann and Robert H. Lurie Children's Hospital of Chicago; Mark Sorenson at University of Iowa Hospitals and Clinics; Nyla A. Heerema and Julie M. Gastier-Foster at The Ohio State University School of Medicine; Andrew A. Carroll at the University of Alabama at Birmingham; Michael J. Borowitz at Johns Hopkins Medical Institutions; Brent L. Wood at University of Washington; Cheryl L. Willman at University of New Mexico; Naomi J. Winick at University of Texas Southwestern Medical Center, Dallas; and Stephen P. Hunger at Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania.\nThe clinical protocol also examined how to best use a steroid formulation called decadron to treat high-risk ALL patients.\nThis was a large-scale study involving pediatric cancer centers across the country.\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear at the end that the treatment of this disease is improving thanks to refinement of the use of existing drug treatments, meaning that they are readily available for patient use.", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that Lyrica is available for the treatment of pain, but that it is not yet approved for fibromyalgia.\u00a0 \nThe story stated that \"Pfizer is expecting word form the Food and Drug Administartion on its application this year\".\u00a0 However a search through www.clinicaltrials.gov shows that there are two phase\u00a0III (trials to\u00a0look at effectiveness of a treatment)\u00a0trials of this drug for the treatment of fibromyalgia that are currently recruiting patients.\u00a0 This would suggest that it will take more time than till the end of this year before the FDA will make a decision about approving this use of the drug.\nNonethless, we'll give the story the benefit of the doubt on this criterion.\u00a0 ", "answer": 1}, {"article": "\"It's automatically responsive to our body function, producing stimulation when needed,\" says Wang.\nThis research was supported by grants from the National Institutes of Health (R01EB021336 and P30CA014520).\nResults of the study were published today (Dec. 17, 2018) in the journal Nature Communications.\nThat existing unit, \"Maestro,\" approved by the Food and Drug Administration in 2015, administers high-frequency zaps to the vagus nerve to shut down all communication between the brain and stomach.\nThat means the device only stimulates the vagus nerve when the stomach moves.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the device is experimental, and that further animal and human testing lie ahead.", "answer": 1}, {"article": "Metastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.\nThe study employed the monoclonal antibody nivolumab, one of the drugs represented among the growing arsenal of immunotherapy therapies.\nThe drug frees the immune system to attack cancer by disrupting a brake that halts immune response.\nA rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.\n\"This the first formal clinical trial completed with patients with previously treated metastatic SCCA,\" said Morris.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release squeaks through here, describing nivolumab as \u201cone of the drugs represented among the growing arsenal of immnotherapy therapies.\u201d This might imply to the reader that the drug is already available to treat other conditions. However, it does not state specifically whether the drug has FDA approval for anal cancer or any other application.", "answer": 1}, {"article": "\"Preventing or lessening the severity of an allergic reaction to a food you've ingested that you're allergic to is kind of the holy grail of food allergy treatment,\" Bochner said.\nAnne Marie Singh and Melanie Dispenza are now testing how successful the drug is at targeting allergies to food, such as tree nuts and peanuts.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\nThe study was funded by a 2016 Dixon Translational Research Grant.\nThe findings were published in the Journal of Allergy and Clinical Immunology in May.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is clear that the drug is still being studied. It does not make any claims about when such treatments might be available.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story accurately describes\u00a0Deplin\u2019s status as a \u201cmedical food\u201d\u00a0and notes that physician supervision is required while taking Deplin.", "answer": 1}, {"article": "Ishdori A, Capps O, Murano PS.\nToday, as the largest vegetable commodity board, the USPB is proud to be recognized as an innovator in the produce industry and dedicated to positioning potatoes as a nutrition powerhouse--truly, goodness unearthed.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nFor more nutrition information and to access a vast collection of healthy potato recipes, please visit http://www.\nThe executive summary \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is available online at http://advances.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We think it\u2019s obvious that potatoes are widely available.", "answer": 2}, {"article": "Surgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nStraiton didn\u2019t respond to emails seeking comment.\n\u201cReplacing the aortic valve improves functional capacity,\u201d Kapadia, who wasn\u2019t involved in the study, said by email.\nOn average, they added almost 42 meters (138 feet) to their performance before surgery.\n\u201cThese symptoms lead to reduced functional capacity (inability to perform physical exertion) and also impact a patient\u2019s overall sense of wellbeing and quality of life,\u201d Cohen, who wasn\u2019t involved in the study, said by email.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss how widely available these procedure are.", "answer": 0}, {"article": "However, common side effects included headache, dizziness and nausea.\n\"Among those who remained, lorcaserin produced relatively modest weight loss when combined with diet and exercise counseling, and that weight loss was maintained in over half of the participants only so long as they kept taking the drug.\nWEDNESDAY, July 14, 2010 (HealthDay News) -- A weight-loss pill called lorcaserin not only helps people drop pounds but does so with few side effects, new industry-funded research reports.\nFDA briefing documents posted online Tuesday acknowledged Qnexa's effectiveness in helping patients lose weight, but said the review panel should take into account a number of potential nervous system and psychiatric side effects, the Associated Press reported.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is a drug company study of a drug that is \"being considered for approval\"\u00a0by the FDA.\" It\u00a0gives a bit of a timeline but could have said\u00a0how long it might take before the drug, if approved, hits shelves.", "answer": 1}, {"article": "Tiny channels collect perspiration and route it to different compartments where it interacts with chemicals that change color to reflect sweat loss, the perspiration\u2019s acidity level, and concentrations of chloride, glucose and lactate.\nThe experimental gadget goes well beyond activity monitors like the Fitbit.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\nThe skin-like sweat patch adds a capability called microfluidics, capturing and analyzing tiny amounts of body fluid.\nA little larger than a quarter, it\u2019s almost like a tiny lab stuck to the skin \u2014 and a study published Wednesday found it worked on sweaty bicyclists, sticking even during a long-distance race in Arizona.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t describes the steps that need to be taken for this technology to become available to consumers and clinicians. Beyond calling the device \u201cexperimental,\u201d it gives no sense as to how close the device is to being marketed. \u00a0", "answer": 0}, {"article": "Common symptoms in the aftermath of concussion include confusion, headache, changes in vision or hearing, thinking or memory problems, fatigue, sleep changes and mood changes.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nAlthough effective drug treatments for mTBI await discovery, rest and counseling are known to be helpful for patients, Mukherjee said.\nIn the new study, the researchers focused on well-known networks of activity that are observed when the brain is in a resting state.\n\"We may be able to use this information to help guide treatment decisions and counseling of patients early on, when it may be more effective.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Compared to other imaging technologies like MRI and CT, fMRI is not as widespread, but it\u2019s becoming increasingly common as a diagnostic method to assess brain function. Most academic centers are equipped with fMRI machines, especially hospitals conducting neuroscience research.\nSince the news release doesn\u2019t discuss availability, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The author acknowledges that the initial clinical trial, in which the featured patient is participating, will take two more years and that that two additional clinical trials would have to demonstrate safety and efficacy of the drug before it could receive FDA approval. This was a strong point in the story.", "answer": 1}, {"article": "\u201cIt is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.\u201d\n\nNocturia (wakening at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.\nNoctiva is the first FDA-approved treatment for this condition.\nNoctiva is being approved with a boxed warning and a Medication Guide because it can cause low sodium levels in the blood (hyponatremia).\nNoctiva should not be used in children.\nAlthough there are other FDA-approved medications that also contain desmopressin, none of those medications are approved to treat nocturia.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release mentions that this drug is already approved for other uses and that the newly approved therapy is manufactured by Renaissance Lakewood for Serenity Pharmaceuticals.", "answer": 1}, {"article": "\u201cIf screening is going to work, you\u2019ve got to keep at it.\u201d\nIt is not clear when or how guidelines for lung cancer screening could be drawn up, and until they are, insurers including government programs such as Medicare are unlikely to pay the average $300 cost of a scan.\nThe high so-called \u201cfalse positive\u201d rate is an issue, said Dr. James Hanley of McGill University, who also reviewed the findings for Reuters Health, but many mammograms also find lesions that turn out to be benign.\nThe data are \u201cconsistent\u201d with earlier studies but there are still many issues to resolve regarding lung cancer screening, Johnson said.\nFurthermore, an April study showed that 21 percent of a patient\u2019s initial lung CT scans show suspicious lesions that turn out not to be cancer, but lead to needless invasive follow-up procedures and radiation exposure, as well as stress and anxiety for patients and their families.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nAlthough this story does not directly address the availability of CT screening specifically designed to identify lung tumors, it does point out that such screening is generally not covered by insurance.", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that 140,000 women per year get breast reduction surgery. This clearly implies wide availability. ", "answer": 1}, {"article": "SHP465 (triple-bead mixed amphetamine salts - MAS) is an investigational oral stimulant medication being evaluated in the U.S. as a potential treatment for ADHD, a therapeutic area with significant need for additional treatment options.\nOnce the pharmacokinetic study and an additional safety and efficacy Phase 3 trial in adults currently under way are complete later this year, Shire plans to add these study results to its existing SHP465 data set to submit a Class 2 resubmission for FDA approval of the medicine for treatment of ADHD.\nStatements included herein that are not historical facts, including without limitation statements concerning our announced business combination with Baxalta and the timing and financial and strategic benefits thereof, our 20x20 ambition that targets $20 billion in combined product sales by 2020, as well as other targets for future financial results, capital structure, performance and sustainability of the combined company, the combined company's future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products are forward-looking statements.\n\n\u2022 Study addresses key U.S. Food and Drug Administration (FDA) requirement, keeping SHP465 on track for potential 2017 U.S. launch\n\u2022 Key secondary endpoint also met, showing higher proportion of patients were rated improved (p<0.001)\n\u2022 Data add to overall robust clinical development program for SHP465\n\nShire plc (LSE: SHP,NASDAQ: SHPG) today announces positive topline results from a four-week Phase 3, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, safety and efficacy study, SHP465-305, in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).\n\"These results represent an important step toward a new treatment option for patients with ADHD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states the drug maker hopes to begin marketing the drug during the second half of 2017, after clearing FDA approval. We often look skeptically upon predictions of when a drug may be approved, especially when those predictions come from those with a vested interested, but this date seems far enough off that it won\u2019t raise false hopes.", "answer": 1}, {"article": "Many groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\nThey were meant to spare women some of the worry and expense of extra tests needed to distinguish between cancer and harmless lumps.\nShe said breast mammograms have contributed significantly to reducing deaths from breast cancer, a fact that should not be ignored in favor of mathematical models.\nHis team calculated that a woman who gets a yearly mammogram starting at age 40 cuts her risk of dying from breast cancer by 71 percent compared to a 23 percent reduction in risk if a woman followed the task force recommendations.\nIt kills 500,000 people globally every year and is diagnosed in close to 1.3 million people around the world.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There\u2019s no question about the availability of mammograms.", "answer": 2}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nO'Shaughnessy, who is co-director of breast cancer research at Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology in Dallas, said the results of a larger (about 500 patients) phase 3 trial should be available within one to three months.\nThis may not seen like very long in either group, but for this serious a cancer, it is impressive, the researchers noted.\nAmong them, she said, were the small size of the study group, \"imbalances at baseline\" favoring the iniparib group, and the \"unconventional\" chemotherapy regimen.\nMore than one-half of the women responded to the combination treatment (meaning the tumor volume decreased) versus only about one-third of those receiving chemo alone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug is experimental & that the results reported are from a Phase 2 trial.\u00a0 Results from a larger Phase 3 trial of 500 women will be available in 2-3 months.\u00a0 Information about whether the drug has FDA approval or whether it is currently used for treating other diseases would have been helpful.", "answer": 1}, {"article": "It usually starts as a rash on one side of the face or body, often causing pain, itching and tingling.\nThe CDC has more on the shingles vaccine.\nA study of a cross-section of adults enrolled with a health-management organization in southern California shows that the vaccine provides protection for many older adults without many side effects.\n\"It's protecting against a severe disease, particularly in elderly adults,\" he said, \"so the benefit, I think, is overwhelming that we should be using this because it's recommended.\"\nBut the vaccine can cost a couple of hundred dollars, he said, perhaps making it out of reach for those with limited resources.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that the vaccine has been available since 2006. ", "answer": 1}, {"article": "The children were randomly assigned to one of two groups.\nParents have long suspected that sugary foods might be a culprit in inducing symptoms, but there's not a lot of evidence to support this theory, according to the NIMH.\n\"Measuring IgG levels in kids doesn't seem helpful,\" Ghuman said, but it does look as if the elimination diet may help some children.\nGhuman said that this study doesn't answer a number of questions, such as whether or not the elimination diet reduces symptoms long-term.\n\"But, for this diet to work, you have to be very consistent with it, and you have to pay attention to nutrition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described the diet, allowing readers, especially parents, to understand at least the basics of what it would entail. The problem with both stories, though, was that they did not say anything about food preparation. Is serving a child fried chicken the same as grilled? Are french fries as good as a baked potato? In fairness, the studies that are cited by this study don\u2019t provide good detail on the food preparation, either. There are so many fad diets out there claiming to help children with a range of behavioral disorders that we thought as much guidance as possible would be important. Still, we thought enough detail was presented to warrant a satisfactory rating.\n", "answer": 1}, {"article": "It's not known, she said, whether there is a true association or whether it may be due to chance or another factor.\nThe drugs are believed to work by preventing stress hormones from stimulating cancer cells.\nPrevious research, Lichtenfeld said, has found a reduced rate of skin cancer among men who take another type of blood pressure-lowering drug.\nThose on beta blockers also had a 57 percent reduced risk of getting a secondary cancer.\n\"Beta- blocker drugs compete with stress hormones and bind to the same target receptors [on a cellular level], but unlike stress hormones, do not activate cancer cells,\" said Dr. Des Powe, a senior healthcare research scientist at Queen's Medical Centre, Nottingham University Hospital NHS Trust, in Nottingham, England.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beta blockers are widely used to treat a variety of conditions, including high blood pressure, and their availability is not in question.", "answer": 2}, {"article": "\"I'm keeping things ready for when they get the green light,\" he said.\nDue to his improvements, the research team is developing a system that McGlynn can use at home and outside.\nWith the technology switched on, he covered far more ground and his pace was twice as fast during his 30-week study.\nOnce we got it fine-tuned and I got walking, I thought it was amazing.\nThe researchers hope these studies will lay the foundation for implanted systems that restore some independence to people with MS or who have suffered a stroke.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We would have liked to see discussion of what hurdles this technology must overcome to be made available to the general patient population, as well as what types of patients might stand to benefit.", "answer": 0}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\nBased on the CheckMate-025 findings, earlier this month (September 16) the FDA granted Breakthrough Therapy Designation to nivolumab for the potential indication of metastatic RCC.\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\nThe study included 821 patients with advanced RCC across 151 sites in 24 countries in North America, Europe, Australia, South America and Asia.\nThe Breakthrough Therapy designation is intended to expedite the development and review of medicines with early signals of clinical benefit in serious diseases to help ensure patients have access to new therapies as soon as possible.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that \u201cNivolumab, marketed as Opdivo, is currently used to treat metastatic melanoma and advanced non-small cell lung cancer.\u201d\u00a0 However it is silent on the availability of everolimus (Afinitor). The release also did not mention insurance coverage for these treatments.", "answer": 0}, {"article": "To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years.\nThe study authors pointed out linagliptin was licensed in 2011 and this is the first long-term study examining its safety and effectiveness.\nThey added more research is needed to confirm their findings.\nThe results of a larger, ongoing study currently underway may help resolve the issue of whether the newer drug is worth the extra money, Weiss said.\nThe researchers noted that which drug they should be prescribed is unclear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from the story whether this drug is available anywhere. You could interpret the story both ways. \u201cThe study authors pointed out linagliptin was licensed in 2011 and this is the first long-term study examining its safety and effectiveness. They added more research is needed to confirm their findings.\u201d", "answer": 0}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\nBut they are not to be underestimated.\nStephanie Yao, a spokeswoman at the F.D.A., wrote in an e-mail that any item that uses melatonin \u201cas an additive may be subject to regulatory action.\u201d\n\nThat is why the makers of these new baked goods label them \u201cNot for food use.\u201d They want them to be considered dietary supplements, which do not need the F.D.A.\u2019s premarket approval and are not required to be proved safe or effective.\nAnd yet Tracy Evans, who owns a bar where musicians perform in Erie, Pa., that has sold hundreds of Lazy Cakes, said she instructs employees to tell partygoers, \u201cI highly recommend you wait to where you\u2019re going to be at the end of the night before eating.\u201d\n\nWhy?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widening availability of these products is eminently clear from the story.\u00a0 And the fact that melatonin has not approved by the FDA as a food additive is explained.", "answer": 1}, {"article": "\"It's clear we need more efficacious drugs with milder side effects.\"\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nFrom 20 to 45 percent of people who score high on the scale go on to develop full-blown psychosis, in which these symptoms become extreme, researchers have found.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\n\"This might discourage people, and legitimately so, from using this drug for prevention because of the weight gain, but hopefully it won't discourage study\" of other drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Zyprexa is not FDA approved for prevention of psychosis in patients identified at high-risk. The story mentions that this was a preliminary trial and explains that the idea of identifying patients at high-risk of developing a psychotic disorder and treating them with a drug like Zyprexa is still very new, controversial and has several risks, with very limited long-term benefit. ", "answer": 1}, {"article": "(Reuters Health) - People struggling with irritable bowel syndrome (IBS) might feel better with antidepressants or psychotherapy, a recent study suggests.\nOne limitation of the current study is that the smaller studies used in the analysis had a wide variety of designs and methods for testing the success of treatment, researchers note.\nAlthough the use of antidepressants is common among IBS patients, psychotherapy is not, the study authors note.\nAntidepressants may work better for certain types of IBS, and the study findings also suggest that the type of medication may matter, Kulak-Bejda said by email.\n\u201cThe decision should be made after considering all the pros and cons.\u201d\n\nLead author Dr. Alexander Ford of the University of Leeds in the U.K. didn\u2019t respond to requests for comment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t specifically state that the antidepressants and treatment options studied in these various trials are available for clinical use. However, we think it can be broadly assumed that readers know these treatment options are available. As such, we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "(PHILADELPHIA) -- When patients present with neurologic symptoms such as severe headaches or seizures, the symptoms could suggest anything from infection, cancer, or an autoimmune disease of the brain or spinal cord, leaving physicians scrambling to find the cause in a short amount of time.\n\u201cOnce confirmed with additional research, our test could provide a first, rapid and less invasive way to look at what\u2019s happening in the brain and guide treatment or further testing.\u201d\n\nThe results were published in the journal PLOS ONE on October 31st.\nThe diagnostic could prove particularly useful in infants and young children.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\nNow, researchers at Jefferson (Philadelphia University + Thomas Jefferson University) have developed a test that could rapidly parse out infections of the brain from other diseases.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although a doctor\u2019s office test is teased, the release makes clear that it needs to be \u201cconfirmed with additional research.\u201d\nThere are a number of steps ahead before we know if this will indeed be available.", "answer": 1}, {"article": "She also called on physicians not to overscreen patients for vitamin D deficiencies, a practice that can lead to overprescribing it.\nI think there's a general perception that if some is good, more is better.\nThis practice isn't totally harmless.\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t go into this, but it doesn\u2019t really need to. Vitamin D supplements are available online and have long been available in many grocery, drug, and health stores. We\u2019ll rate it not applicable.", "answer": 2}, {"article": "At the annual Alzheimer\u2019s Association International Conference, researchers say they have found a series of substances in saliva that can distinguish between people who experience normal aging, those with mild cognitive dementia (MCI, which in some cases can lead to Alzheimer\u2019s and in other cases not), and Alzheimer\u2019s disease.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We give credit here for this acknowledgment: \u201cThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s.\u201d However, readers overall may get the impression that the test\u2019s clinical usage is coming soon, when that\u2019s not likely the case. We\u2019d be much more comfortable if the story included more information accurately portraying the tentative nature of the findings, findings that might be actually caused by other factors not studied.", "answer": 1}, {"article": "Sigmund Freud often included one of his dogs in psychoanalysis sessions.\nIn other words, people are recognizing that anecdote isn\u2019t enough.\u201d\n\nUsing animals in mental health settings is nothing new.\nCherry-picked positive results also are a problem, as he says happens in promotional materials from the Human-Animal Bond Research Initiative (HABRI).\nBut the popular embrace of pets as furry therapists is causing growing discomfort among some researchers in the field, who say it has raced far ahead of scientific evidence.\nThe study was designed to avoid some of the pitfalls that Crossman has seen elsewhere, which is why some of the 78 young participants got to play only with a fuzzy blanket \u2014 because tactile stimulation is known to reduce stress \u2014 and why others simply waited for the 15 minutes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that therapy animals are in widespread use, and offers numerous related examples. However, people may wonder how to get one, and whether their insurance would pay.", "answer": 1}, {"article": "Hospitals take over with more sophisticated cooling equipment.\n\"I am still amazed that lots of physicians are not aware of the technology,\" Blitz said in an e-mail.\nThough it's not unusual to have debate over new therapies, the benefits of induced hypothermia is not a new discovery.\n\"And if they are aware, they are not using it.\"\nIt's the most common cause of sudden cardiac arrest.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that availability of this treatment varied around the country.", "answer": 1}, {"article": "The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting, and education and advocacy to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head, and neck.\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\nThe time required to transfer a patient from their CT scan to the operating room could delay EVT by as long as 60 minutes.\nThe study, New Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?, shows that recent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient with large vessel occlusion (LVO) for an endovascular thrombectomy (EVT).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear if this software is already on the market or if it is in the early stages of development. Given that the study, which was presented at a conference, is subtitled \u201cAre We Ready for Prime Time?\u201d this is an issue that the researchers were planning to address \u2014 but no hint of that information is in the release.", "answer": 0}, {"article": "Those who reported eating nearly three servings of fruit a day on average had a 25% lower risk of developing breast cancer than those who ate half a serving of fruit.\nMORE: Mediterranean Diet With Olive Oil Linked to Lower Breast Cancer Risk\n\n\u201cThis study underscores the importance of what a young girl eats for her future health,\u201d says Farvid.\nThe results also underscore the importance of eating whole fruit, rather than fruit juice.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fruit has been around longer than humans have, so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "ORMD-0801 goes from the gut to the liver, while injected insulin circulates throughout the body before it gets there.\nBut the data from the Phase II, 180-patient trial represents a major milestone.\nOramed said it plans to publish more detailed data from the study once it has had time to analyze the full results.\nThe positive results must be replicated in a larger Phase III trial before the drug, known as ORMD-0801, can be submitted for approval.\nThey were dosed before bed time and had their overnight glucose levels continuously monitored.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug needs more research before it will be reviewed by the FDA for approval.", "answer": 1}, {"article": "(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\n\u201cTaking care of your vision is important in order to maintain good cognitive function,\u201d she said in a telephone interview.\n\u201cIf you\u2019re aging without good vision, not only are you giving your brain less stimulation, you might be altering your brain at a structural level,\u201d she said in a phone interview.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that the vision treatments mentioned (\u201ca new eyeglass prescription or surgery to remove cataracts\u201d) are available in the marketplace, which is accurate.", "answer": 1}, {"article": "According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\nBoth drugs are \"immunotherapies,\" which work by boosting the immune system's ability to spot and destroy tumor cells.\nBoth Opdivo and Yervoy are already approved by the U.S. Food and Drug Administration to treat advanced (metastatic) melanoma.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains: \u201cBoth Opdivo and Yervoy are already approved by the U.S. Food and Drug Administration to treat advanced (metastatic) melanoma. In some patients, the drugs are used in combination.\u201d", "answer": 1}, {"article": "The National Institute on Deafness and Other Communication Disorders estimates that 26 million Americans between the ages of 20 and 69 have high-frequency hearing loss.\nMED-EL expects that the SYNCHRONY EAS Hearing Implant System will be available in the coming months.\nSYNCHRONY EAS (Electric Acoustic Stimulation) Hearing Implant System, which is manufactured by Durham-based MED-EL Corporation, received FDA approval on September 16.\n\u201cOn average, patients performed more than twice as well on tests of speech understanding with EAS than they did with their hearing aids preoperatively, which speaks to the benefits of this technology,\u201d Pillsbury said.\nUNC participated in the EAS System clinical trials and implanted the device in more patients than any other hearing center that participated.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the device received FDA approval on September 16.and that it will be available \u201cin coming months.\u201d", "answer": 1}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear this drug is still in development.", "answer": 1}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tells readers exactly where they can buy an Alex device, and notes that the Text Neck Indicator is an Android app that is already on the market.", "answer": 1}, {"article": "In Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nThere are more than 100 algae-derived ingredients used in cosmetics worldwide, Mrs. Lewis said.\n\u201cThere are ingredient suppliers that provide ingredients to health care, food and drink industries, and cosmetic companies,\u201d she said.\n\u201cBut if it doesn\u2019t deliver, it\u2019s not a business that we can do.\u201d\n\u201cIn the petri dish, their data seems to show some substantial benefits to their active ingredient,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story starts out by making it clear that \u201cAlgenist moisturizers, serum and eye balm are already available at Sephora.com and will go on sale in the company\u2019s stores this week.\u201d", "answer": 1}, {"article": "Learn more about omega-3 fatty acids, including DHA, and infant health from the March of Dimes.\nAnd, in the case of colds, the probability of a cold was slightly less.\nBut, she added that the supplements did appear to be safe for pregnant women to take.\n\"The data suggested that for most of the symptoms we looked at, duration of symptoms was less when mothers received DHA.\nTherefore, the current study looked at DHA supplements derived from algae.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never did explicity state whether the product used in the study was generally available or not. One might be able to assume that it is, but it would have only required a line in the story to address availability and how widespread is its use.", "answer": 0}, {"article": "(Health.com) -- People who consume lots of foods rich in vitamin B12 -- such as fish and fortified cereals -- may be at lower risk of developing Alzheimer's disease than people who take in less of the vitamin, a small study conducted in Finland suggests.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\nMaria Carillo, Ph.D., the senior director of medical and scientific relations at the Alzheimer's Association, a nonprofit research and advocacy group, urges caution in interpreting the new findings, especially given that so few study participants developed the disease.\nAnd he worries that the results may spur doctors to recommend B12 injections to their patients -- a preventive treatment that he says is unfounded and already overused.\n\"The role of supplementation remains unclear.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Statins reduce cardiovascular risk and scientists believe it is because they decrease low-density lipoprotein, or LDL, the so-called bad cholesterol.\nBoth drugs could win approval from the Food and Drug Administration by this summer.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\n\u201cManaged care pharmacy, indeed the health care system, has never seen a challenge like this to our resilience in absorbing costs,\u201d they wrote in the Health Affairs blog.\nIn the studies detailed on Sunday, both drugs reduced the bad cholesterol by about 60 percent, to about 50 milligrams per deciliter from about 120 at the start of the studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article made it clear that these drugs are in development and not approved by the US Food and Drug Administration, but that such approval could come as early as this summer.", "answer": 1}, {"article": "Aug. 30, 2010 -- Three puffs a day of cannabis, better known as marijuana, helps people with chronic nerve pain due to injury or surgery feel less pain and sleep better, a Canadian team has found.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Naloxone is a prescription drug that can reverse the effects of prescription opioid and heroin overdose, and can be life-saving if administered in time.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\nA majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\n\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\nCDC also improves patient safety by equipping health care providers with data, tools, and guidance so they can make informed treatment decisions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The major point of this release is that not enough EMS staff are administering the drug. It could have been made more clear that the drug is widely available for EMS staff, but that only a select few EMS staff can administer it in most states. But we think this passes the test.", "answer": 1}, {"article": "It needs to be tested in large trials,\" he said.\nWhether these methods would have produced better results isn't clear.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\n\"The jury is out on that.\nJolly isn't sure why removing clots causes additional problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention the availability of either of these procedures, but assumes that both are readily available and widespread. That\u2019s accurate.", "answer": 1}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job explaining what are basically three different approaches to varicose vein treatment: a surgical option, which is the most common; an injectable drug option, which is becoming more common; and the foaming injectable option, which some doctors use off label.", "answer": 1}, {"article": "For more on irregular heartbeats, visit the U.S. National Library of Medicine.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nIn essence, the new intervention -- known as \"visually guided laser-balloon catheter\" -- enables doctors to much more accurately target the so-called \"misfiring cells\" that emit the irregular electrical impulses that can cause an erratic heartbeat.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is never made clear whether the device and approach are still experimental or already in clinical use. ", "answer": 0}, {"article": "The higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nMichalsky says the study is ongoing, and they expect to continuing gathering information for years to come.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\n\"One of the surprises was that almost all patients benefited as a result of the surgery,\" says M. James Lenhard, the medical director of Christiana Care Health System's Diabetes & Metabolic Diseases Center in Wilmington, Del., who was not involved in the study.\nBefore undergoing bariatric surgery, teens and their families receive extensive counseling, Michalsky says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that 1,600 teens undergo stomach reduction surgeries each year, which suggests that they are widely available. It also mentions the need to seek counseling and \u201cdetailed information from well-established bariatric surgery centers that are specifically dedicated to treating adolescents.\u201d\nHowever, one big key to availability is insurance coverage\u2013and this was not mentioned.", "answer": 1}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nHowever, these over-the-counter supplements have not undergone clinical trials to see if they work in people.\nBrenner is a consultant for ChromaDex.\nThe human trial involved six men and six women, all healthy.\nThe information from the mouse study subsequently helped Brenner's team design the formal clinical trial.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that the supplements are commercially available.", "answer": 1}, {"article": "\"I would have bandages on me all the time.\nBut there's a catch often not understood by those who undergo the procedure: Once they lose the weight the surgery helps them lose, there may be more surgery to come -- surgery that is costlier and riskier and that requires a longer recovery time than the original operation.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nIntense discomfort that interferes with activity is a common problem after bariatric surgery, says plastic surgeon Sarah Holland, an instructor at Columbia University Medical Center in New York -- and it can be almost constant.\nThe American Society of Plastic Surgery (ASPS) has formed a task force -- D'Amico is a co-chair -- to alert doctors to the higher risks involved and teach them new techniques.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says this has been \u201ca hot topic at all the national conferences over the last couple of years\u201d. It is unclear as to whether this indicates that there are lots of adequately trained plastic surgeons who are trained for these types of procedures or whether it is only available at certain centers. It is perhaps telling that one plastic surgeon interviewed stated that the increase in need for surgical revisions required after contouring procedures is because there are surgeons who \u201clack adequate experience\u201d. The article would have been much more valuable to readers if it had provided some guidance for how consumers might evaluate the skill and proficiency of a plastic surgeon they were considering consulting for this type of work. ", "answer": 0}, {"article": "Their median age was in the mid-50s, and they were followed for a median of 6.3 years.\nThe new findings are part of a trend to move away from radical surgery for breast cancer.\nBut Dr. Carlson said that some of his colleagues, even after hearing the new study results, still thought the nodes should be removed.\nBut doctors have continued to think that even microscopic disease in the lymph nodes should be cut out to improve the odds of survival.\nThey were so sure cancerous nodes had to come out that they said the study was unethical and would endanger women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that removing all under-arm lymph nodes is the standard of care for women with breast cancer and that feelings about that standard are entrenched.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nCalled Zostavax, the shingles vaccine is made by Merck.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nThe new study is published in the Journal of the American Medical Association.\nThe associated pain can last months or even years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that this shingles vaccine has been available in the Untied States since 2006.", "answer": 1}, {"article": "Improvements were seen in bone density in the hip as well, but they were not statistically significant.\nThey were each given a DVD of the 12 yoga poses used in the pilot study and an online program in which to record what they did and how often.\nYoga enthusiasts link the practice to a long list of health benefits, including greater flexibility and range of motion, stronger muscles, better posture and balance, reduced emotional and physical stress, and increased self-awareness and self-esteem.\nIn addition, \u201cYoga is good for range of motion, strength, coordination and reduced anxiety,\u201d he said, \u201call of which contribute to the ability to stay upright and not fall.\nFor years, he has been gathering evidence on yoga and bone health, hoping to determine whether yoga might be an effective therapy for osteoporosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yoga is everywhere (the phrase \u201912 important yoga poses\u2019 gives 6.2 million hits on google).", "answer": 1}, {"article": "Generalized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\n\u201cTelephone-delivered psychotherapy is one way to overcome some barriers to mental health treatment that rural older adults face,\u201d the study concludes.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nThis work was supported by grants from the National Institutes of Health and funding from the Taylor Family Institute for Innovative Psychiatric Research.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the telephone is ubiquitous in modern life, one assumes that such a program as explained in this clinical trial could be available in short notice, assuming financial support for the project.", "answer": 1}, {"article": "\"It's still new and it's quite different than previous genetic testing that's been available,\" says Norton.\nIt's only been on the market since October 2011 and is not regulated by the Food and Drug Administration \u2014 the FDA does not regulate this type of genetic testing service.\nHe says the technology is so new that a lot of doctors have no experience with it, and consumers need to understand that.\nSome worry that the companies' websites and marketing materials don't make the limitations clear enough.\nShe didn't want an invasive procedure like amniocentesis or chorionic villus sampling.Those are considered the gold standard for prenatal genetic testing, but doctors must put a needle into the womb to collect cells that contain fetal DNA, which means a small risk of miscarriage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the tests were new to the market (available since 2011), and that many doctors were still not familiar with them. The story made it clear that these tests were not regulated by the FDA.", "answer": 1}, {"article": "In this study, the average age of the men and women was 52.\nFor example, the study included mostly men, so the findings may not apply to women.\nAs with gastric bypass surgery, both of these procedures leave people feeling full faster, according to NIDDK.\nAfter surgery, people feel much fuller, faster.\nAt the study's one-year mark, those who had the bypass had lost 31 percent of their starting weight, but the non-surgical patients had lost just 1 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make it readily clear how accessible these surgeries are, and who is a good candidate for one. Typically, these procedures are for people over a certain body-mass index, for example. And insurance coverage may or may not pay for it.", "answer": 0}, {"article": "Atopic dermatitis is the most common of the many types of eczema; onset typically begins in childhood and can last through adulthood.\nThe FDA granted the application for Dupixent Priority Review and Breakthrough Therapy designation.\n\u201cFDA\u2019s approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nIf patients experience new or worsening eye symptoms such as redness, itching, pain or visual changes, they should consult a health care provider.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Whether or not this medication will be covered by insurance is a huge concern. Its high cost will affect how many people can access this new drug. Its availability should have been addressed in the release.", "answer": 0}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The three popular diet plans discussed in this article\u00a0are\u00a0widely available and have been used by thousand of people in the U.S. and elsewhere.\u00a0 This article does due diligence in pointing out that the dieters in the\u00a0study received support in the workplace to help them stick to their diets.\u00a0 In addition, the study dieters had the advantages of\u00a0purchasing meals in their work cafeteria\u00a0 with color-coded menu information corresponding to their diet requirements.\u00a0\u00a0\u00a0", "answer": 1}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nThis study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the Fluzone high-dose vaccine used in the study was approved by the FDA in 2009.\nA booster dose would currently be considered an \u201coff label\u201d use and may not be covered by insurance.", "answer": 1}, {"article": "The American Cancer Society has more on lymphoma.\n\"Therefore, since physical activity behaviors can be modified, physicians should counsel patients and survivors on the importance of physical activity and encourage them to maintain and, if possible, increase their level of physical activity.\"\nResearch presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals.\nBut the study couldn't prove that more exercise actually caused death risk to drop.\n\"Importantly, our study shows a survival benefit in patients who increase their level of physical activity,\" Pophali said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It can be assumed that readers are aware of their options regarding physical activity.", "answer": 2}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\nThe findings were published in The American Journal of Sports Medicine.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nNEW YORK (Reuters) - Blood injections, especially of platelet-rich blood, into the affected area help relieve the pain associated with \u201ctennis elbow\u201d where other treatment methods have failed, according to a Greek study.\nBoth groups experienced more improvement at 3 and 6 months after the injections, with no significant in pain scores between the treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "For more information on breast cancer, visit the American Cancer Society.\nBitter melon is a common vegetable in India, China and South America, and its extract is used in folk remedies for diabetes because of its blood-sugar lowering capabilities, according to the researchers.\nEating bitter melon could also have a beneficial effect, Ray said.\n\"It has ingredients which are good for the health.\"\nThe bitter melon extract killed only the cancer cells, not the healthy breast cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that bitter melon extract is a popular nutritional supplement and is a common vegetable in India, China and South America. ", "answer": 1}, {"article": "Visit sirweb.org.\n\"Image-guided treatments have expanded the options available for patients with liver cancer from innovative approaches to biopsies to resections to chemo,\" said Raman.\n\"Advanced stage liver tumors, including ones that have spread from other locations, have limited treatment options because the patients can be in poor health; further, the complex structure of the organ can make it difficult to target with standard approaches,\" said Steven S. Raman, M.D., professor of radiology, surgery and urology at the David Geffen School of Medicine, University of California, Los Angeles, and lead author of the study.\n\"This minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\"\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release made it clear that this therapy is still being tested and people with liver cancer should not expect to access it soon except through a clinical trial:\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned. Additional investigation is also planned to test the therapy in combination with a checkpoint inhibitor to activate a stronger immune response.\n\u201cImage-guided treatments have expanded the options available for patients with liver cancer from innovative approaches to biopsies to resections to chemo,\u201d said Raman. \u201cThis is an exciting way to look to the future, but patients living with advanced liver cancer should understand that this treatment will not be available for several years, except through clinical trials.\u201d", "answer": 1}, {"article": "The result: at week 24, all of the patients receiving either dose of ocrelizumab fared better in terms of lesion count than either the placebo or standard treatment groups.\n\"It's not.\"\n\"In fact, there's nothing novel about this at all,\" he said.\n\"So bottom-line, I would not sell this as a major breakthrough in MS,\" cautioned Rodriguez.\nAnd I see no major advantage of this drug versus that older drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the approach \u201cis only in the early stages of exploration.\u201d", "answer": 1}, {"article": "Current ACS prostate screening cancer guidelines recommend that men make an informed decision with their doctor about whether to be tested for prostate cancer.\nThe men in the study were all from the placebo arm, meaning they had not received the drug.\nHigh levels of PSA can be a marker for prostate cancer, although it's far from a perfect screening tool, experts say.\nAnd many prostate cancers are just that -- of little risk to men during their lifetimes, Brawley said.\n\"The velocity didn't add anything more to detecting aggressive prostate cancers.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that PSA tests are readily available.", "answer": 1}, {"article": "Instead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\nBut there\u2019s a problem with a low-FODMAP diet.\nUnless you have specific symptoms that a low-FODMAP diet alleviates, Gibson says, \u201cenjoy your FODMAPs!\u201d\nGibson estimates that, overall, about 10 percent of the population may be FODMAP-sensitive.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article provides a good listing of foods to choose from that are both high and low in FODMAPS. All are widely available.", "answer": 1}, {"article": "Most head and neck cancers are linked to alcohol consumption and to smoking.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nWas it the caffeine?\nProbably not.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable \u2013 the availability of coffee is not in question. ", "answer": 2}, {"article": "Excluding prostate cancer, researchers found about a 12 percent reduction in overall cancer occurrence and said the protective effect seemed to be greater in people who had previously battled cancer.\nHe was not involved in the study.\nThe research was sponsored by the National Institutes of Health.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of multivitamins isn\u2019t an issue.", "answer": 2}, {"article": "Tumors form in the pleura, a thin membrane of cells that line the lungs and chest wall.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nPHILADELPHIA - Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.\nThe standard first-line therapy treatment involves chemotherapy, and currently there is no approved second-line therapy.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Mesothelioma patients would want to know if the drug is available for them and that\u2019s not the case here. As used in a phase 1b study the drug is considered experimental.\nWe are told that this treatment is used for other types of cancer so presumably it\u2019s on the market. There may be a risk that some oncologists will see the release and use the drug \u201coff label\u201d for mesothelioma, since it is available for other conditions.", "answer": 0}, {"article": "The researchers followed a group of men for eight years who had been on TTh and compared them with another group of men who remained untreated for the same time period.\nIn the absence of large, prospective, placebo-controlled clinical trials of longer duration, substantial evidence regarding the safety and risk of testosterone therapy (TTh) with regard to cardiovascular outcomes can only be gleaned from observational studies.\nInsufficient levels of circulating T in men, contributes to frailty and bone loss.\nTo date, there are limited studies comparing the effects of long-term TTh in hypogonadal men who were treated or remained untreated with T.\n\nResearchers at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH), along with researchers in Germany, established a registry to assess long-term effectiveness and safety of T in men.\nAccording to the researchers, long-term TTh in men with hypogonadism appears to be an effective approach to achieve sustained improvements in cardiometabolic function and reduces the risk of CV events.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Testosterone treatment is clearly available although topical preparations are more expensive than injections and insurance companies may balk at covering these treatments.", "answer": 1}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\nLakhan tells WebMD in an email that the extracts were administered orally.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\nAlthough some objective measures of spasticity noted improvement trends, there were no changes found to be significant in post-treatment assessments.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described \"marijuana extracts\" but never clarified whether they were now available or still experimental.\u00a0 Also, many people would want to know how these extracts \u2013 taken by mouth \u2013 differ from smoking marijuana \u2013 which the story never explained. ", "answer": 0}, {"article": "\"Their lungs get more blood so that the exchange of oxygen into the blood can take place smoothly.\"\nLorch also pointed out that this study involved a mostly homogenous population in a country outside the U.S.\n\n\"We should see whether similar effects are seen in higher-risk populations, such as the low socioeconomic population, racial and ethnic minorities and those at higher risk for neurodevelopmental delay,\" Lorch said.\nPreemies who have delayed cord clamping tend to have better blood pressure in the days immediately after birth, need fewer drugs to support blood pressure, need fewer blood transfusions, have less bleeding into the brain and have a lower risk of necrotizing enterocolitis, a life-threatening bowel injury, she said.\nUntil recently, clinicians believed early clamping reduced the risk of hemorrhaging in the mother, but research hasn't borne that out.\nMuch of the research has focused on preterm infants, who appear to benefit most from delayed cord clamping, Rabe said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Hypothetically, a delay in cord-clamping is something equally available to all those who deliver babies and their patients. But in the real world it\u2019s different: A delay is only available to a woman if her doctor/health system decides to offer it (barring the role of patient advocacy). The story didn\u2019t explore how common delayed cord-clamping is, or how willing doctors are to consider it. And unlike the competing USA Today story, it didn\u2019t suggest that women might want to raise the issue with their doctors.", "answer": 0}, {"article": "Dr. Pan\u2019s co-authors were Zhong Ping Duan at Beijing Youan Hospital, Capital Medical University, in Beijing; Er Hei Dai and Bao Shen Zhu at Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang; Shu Qing Zhang and Wen Jing Zhao at Hepatobiliary Disease Hospital of Ji Lin Province, Changchun; Guo-Rong Han and Hong-Xiu Jiang at Second Affiliated Hospital of Southeast University, Nanjing; Yuming Wang at Institute for Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing; Huai Bin Zou at Youan Hospital, Capital Medical University, Beijing; and Huai Hong Zhang at Nanyang Center Hospital, Nanyang, Henan, all for the China Study Group for the Mother-to-Child Transmission of Hepatitis B.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\nMoving forward, longer term, observational studies are needed to confirm the safety of fetal exposure to tenofovir treatment, says Pan.\nThe current standard of care is to provide vaccine and immune globulin to reduce transmission rates.\n\u201cThis study provides strong evidence on how best to care for women infected with hepatitis B during pregnancy and reduce the rate of disease transmission,\u201d says Mark Pochapin, MD, the Sholtz/Leeds Professor of Gastroenterology and director of the Division of Gastroenterology and Hepatology at NYU Langone.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention that tenofovir (marketed as Viread), the drug being tested, is already an FDA approved drug so many readers may not know that it\u2019s available. It was approved by the FDA in 2001 for HIV and in 2008 for chronic hepatitis B.", "answer": 2}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\nThese data led to two subsequent Phase Ib studies, resulting in tucatinib earning FDA fast-track status and the expansion of this study once meant only to demonstrate drug safety into the \"pivotal\" trial that will determine approval.\n'There are women who are alive today because of this drug,' says University of Colorado Cancer center researcher\n\nPhase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer.\n\"Tucatinib could be a substantially practice-changing drug,\" Borges says, meaning that in addition to the drug's current investigations as a third-, fourth-, or more-than-fifth-line treatment, she envisions its use sooner in the arc of breast cancer treatment and with far more patients.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "No information in the news release gives an indication as to when (or if) tucatinib might be widely available.\nThe lead researcher\u2019s comment that \u201cI think this drug has an extremely high likelihood of being approved for women with HER2+ breast cancer for use after previous treatments\u201d is problematic given that the investigative drug is still in early trials and has not yet been FDA approved. ", "answer": 0}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nThe men were assigned to receive either placebo treatments or daily 0.5-milligram doses of Avodart for four years.\nScheduled biopsies were performed two and four years after they entered the trial.\nBut none had evidence of cancer when biopsies were performed within six months of entering the trial.\nThe drugs work by blocking the conversion of testosterone into a key hormone associated with prostate growth.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Avodart, a drug commonly used to treat enlarged prostate, is clearly available. ", "answer": 1}, {"article": "This is a better story.\"\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nRight now the American Cancer society recommends an MRI in addition to a mammogram for women who are at high risk for breast cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Ultrasound machines are typically available in most medical centers. The broadcast does not mention that physicians and ultrasonographers in the study cited were trained using standardized screening protocols.\u00a0 In a real-world clinical setting, the availability of properly trained physicians and technicians can vary, resulting in greater false-negative or false-positive test results.\u00a0 The editorial accompanying the source article states, \"It is questionable whether the diagnostic accuracy achieved in the study..would have been the same if nonradiologists had performed screening ultrasound.\" ", "answer": 0}, {"article": "Nearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\nThe results add to a growing body of evidence linking cocoa consumption to heart health, but they aren\u2019t a free pass to gorge on chocolate.\nFor those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\nNEW YORK (Reuters Health) - A sweet tooth isn\u2019t necessarily bad for your health\u2014 at least not when it comes to chocolate, hints a new study.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of chocolate is not in question. The story appropriately notes that there is a stronger statistical association with dark chocolate as opposed to milk chocolate.", "answer": 1}, {"article": "\"Everyone heals differently.\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\nResults of the study are published in the Jan. 3 issue of the Annals of Internal Medicine.\nFunding for the study was provided by the U.S. National Center for Complementary and Alternative Medicine.\nThere also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that all of the treatments included in this trial are widely available.", "answer": 1}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nBut some doctors believe even if that's the explanation for acupuncture's effectiveness, there's no reason not to offer it if it makes people feel better.\nThat makes the conclusion more robust, said Dr. Andrew Avins, author of an Archives commentary and a physician and researcher with the University of California at San Francisco and Kaiser-Permanente.\nAcupuncture is relatively safe and uncertainty over how it works shouldn't stop doctors from offering it as an option for patients struggling with pain, Avins said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that acupuncture is becoming more mainstream and might be covered in some states under the new health care law. However,\u00a0a dearth of licensed acupuncturists might restrict availability in some areas, especially rural locations. The story could have mentioned this. But we\u2019ll give it the benefit of the doubt for its general discussion of availability.", "answer": 1}, {"article": "47(5) pp.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\n\u201cThere is no magic pill for obesity, but this swallowable balloon and other intragastric balloons may offer new hope to people who otherwise would not seek treatment or not have as good a result with diet and exercise alone,\u201d said Raul J. Rosenthal, MD, ASMBS President and Chairman, Department of General Surgery, Cleveland Clinic Florida, who was not involved in the study.\nThe device is manufactured by Obalon Therapeutics, Inc., based in San Diego, CA.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says that the Obalon device was approved by the FDA in September, so readers might be able to guess that it will be available in the U.S. relatively soon. The release could have noted that the manufacturer will start selling it in this country in January 2017, and that it has been on the market in Europe and other countries for almost three years.", "answer": 1}, {"article": "Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nFor the LIFE study, the researchers analyzed data from 1,635 men and women age 70-89 over an average of 2.6 years.\nThe work is part of the Lifestyle Interventions and Independence for Elders (LIFE) study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The program of exercise training used in the study is not well described but is presumably within the scope of many senior centers and exercise programs designed for the elderly population. The release would ideally have made it clear that the program was not unique and is likely widely available.", "answer": 2}, {"article": "The U.S. National Cancer Institute has more on mammography.\nHe mentioned certain differences in methodology as a possible factor, as well as the possibility that mammographic techniques have improved over the years.\nJonsson, an associate professor of cancer epidemiology at Umea University in Sweden, could not pinpoint exactly why his findings differed from those of other studies.\nThe findings will no doubt do little to quell a controversy that has existed since the 1980s over the value of mammography screenings for women in their 40s.\nThe value of mammograms for women 50 and older is not in question.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not discuss availability of mammography, but such availability is really not in question.\u00a0 So this is judged not applicable because we can\u2019t give it a satisfactory or an unsatisfactory score. ", "answer": 2}, {"article": "In recent years, surgical techniques, anesthesia and other medical care advanced, and death rates fell.\nNot every older person can undergo such a difficult operation, he said but the great results seen in the new studies show that doctors have gotten good at figuring out who can.\nThis improved dramatically as the study went on, from 85 percent in the early years to 98 percent by its end.\nThe studies were reported at an American Heart Association conference this week in New Orleans.\nThat led more doctors to operate on older patients for everything from bum knees to bad backs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story sketched out the possibilities and potential merits for individuals in the 80\u2019s and 90\u2019s to undergo open heart surgery to repair valves and vessels. \u00a0While these types of procedures are widely available, there was no discussion about whether all facilities admitted or were suited to handle older individuals for these sorts of procedures. \u00a0", "answer": 0}, {"article": "About 80,000 people a year are diagnosed with a brain tumor, and about 24,000 of those are malignant.\nBut if the tumor is aggressive, it\u2019s usually fatal.\n\u201cThe nature of the treatment causes side-effects,\u201d Bigner said.\nIt\u2019s not clear why just one in five patients benefits, said Dr. Annick Desjardins, who worked on the study team.\nThese patients have a \u201cdismal\u201d prognosis, the Duke team wrote in the New England Journal of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental treatment and is not widely available.", "answer": 1}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes the staggering sales figures of prescription and over the counter lice control products \u2013 totaling more than $151 million last year \u2013 making availability quite clear.", "answer": 1}, {"article": "\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nInspire is not for everyone.\nFor Siravo, she said her memory is back to 100 percent.\nExhausted, the 59-year-old could barely do her job as a nurse \u2013 and she knew something wasn't right.\nA treatment is offering hope for millions of patients with sleep apnea, a disorder that causes people to stop breathing when they're asleep.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that Inspire is available.", "answer": 1}, {"article": "Kilmer McCully of the V.A.\nThe findings, released yesterday, are the latest in a series of recent studies that have found vitamins and other dietary supplements fail to have the health benefits they are touted for.\n\"These studies did not test whether B vitamins used by healthy people can help keep them healthy.\nVitamins should not be expected to perform like drugs -- their greatest promise is in prevention,\" said Annette Dickinson in a written statement.\nBut Steven E. Nissen, president of the American College of Cardiology, said the findings should end debate about the theory, which had already lost credibility among many scientists.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that B vitamins have been in use for some time by many people for these purposes. ", "answer": 1}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the drug studied, Byetta, was approved by the FDA for selected people with type 2 diabetes in 2005.\u00a0 ", "answer": 1}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nA recent study published in the same journal, co-authored by Professor Tim Newton, showed that more women than men reported dental phobia in the 2009 Adult Dental Health Survey.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nCognitive behavioural therapy could help many people with a dental phobia overcome their fear of visiting the dentist and enable them to receive dental treatment without the need to be sedated, according to a new study by King's College London.\n\"However, there is a need for people with dental phobia to be carefully assessed by trained CBT practitioners working with dental health professionals.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that CBT and sedation are both available to patients with dental fears in the U.K. The release would have been stronger if it had noted, as the journal article does, that: \u201cSome barriers to the broader dissemination of CBT for people with dental phobia seem to remain, e.g. there is a lack of training and a skilled workforce to deliver the techniques.\u201d", "answer": 1}, {"article": "Watching her patients undergo bone marrow transplant ?\nEach patient's therapy was created just for them in a specialized Fred Hutch facility.\nChapuis's role in this trial is on the laboratory side of the research, ensuring the quality of the genetically engineered cell products and monitoring the activity of the cells after infusion.\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release reports that this is the first test of this particular treatment, so it is clear that it is just at the beginning of the research process.", "answer": 1}, {"article": "Successful methods such as chemotherapy work by killing the cancer cells, but they also destroy healthy tissue.\nAt the moment, fewer than 1% of cancer patients are treated with proton therapy, but Jongen is hopeful that smaller and cheaper machines will be the game changer.\nWhile the proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms, Jongen's Brussels-based company IBA is working on a smaller and cheaper model they hope will make proton therapy more accessible.\n(CNN) Even after decades of battling one of the world's biggest killers, the treatment of cancer is still an inexact science.\nOther centers, however, are currently in development.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reader is told that there are a limited number of sites (and none in England) offering proton beam therapy, but that hope is on the way in the form of a less expensive device from Mr. Jongen\u2019s company. The story states that \u201cthe proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms,\u201d but it doesn\u2019t explain where they are.\nNonetheless, we\u2019ll give the story the benefit of the doubt for supplying a general overview.", "answer": 1}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear, even in the headline, that these are the results of a trial and that there currently is no product even in the FDA pipeline. It also talks about a drug therapy from Johnson &\u00a0Johnson and where it is being sold. It says at one point in the story that the \"findings of both trials had previously been made public.\" It would have been nice to know where, how and why. Presumably at previous conferences, and, if so, why is this treatment not already in the FDA\u00a0pipeline. Reporters should always be wary of scientists, especially corporate ones, who are using the trade show circuit to build momentum for their product instead of following a rigorous peer review process.", "answer": 1}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nLehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear that this treatment is available in Europe, but not in the United States.", "answer": 1}, {"article": "Some leading prostate specialists, like Dr. Scardino, say they are recommending that men who worry about prostate cancer take finasteride.\nHe also ponders taking it himself.\nThat seemed to leave the drug dead.\nThe study researchers, though, wondered if that conclusion was correct.\n\u201cMost of the time, treatment wouldn\u2019t help and may not be necessary.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story accurately mentions the availability of this drug as a prescription medication.", "answer": 1}, {"article": "\u201cAccording to NOAA\u2019s own statistics, per capita consumption of seafood has risen from 14.8 pounds in 2001 to 16.6 pounds in 2004.\u201d\n\nJane Houlihan, the research director of the Environmental Working Group, another advocacy group, said, \u201cThe Harvard study reads like an advertisement for the seafood industry.\u201d\n\nBoth studies reinforce advice from the Food and Drug Administration and the Environmental Protection Agency in 2004, to eat about six ounces of fish a week, preferably high in omega-3\u2019s, with a caveat for women of childbearing age and children under 12 not to eat swordfish, shark, tile fish or king mackerel and to limit their intake of albacore (white meat) tuna to six ounces a week to avoid mercury.\nThe two studies, which conflict in important aspects, seem unlikely to provide much clarity.\nto eat tuna,\u201d Ms. Houlihan said.\nBoth reports have come under criticism from environmental groups and from the Consumers Union.\n\u201cIn addition to being concerned about the failure of the JAMA and I.O.M.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn't any doubt about the availability of fish.", "answer": 1}, {"article": "Load up on berries.\nAnd if they're out of season, like now, studies show frozen berries have similar levels of beneficial compounds.\nIn recent years, regular consumption of berries has been linked to better brain health and a decreased risk of Type 2 diabetes.\nWomen With A Berry-Snacking Habit May Have Healthier Hearts\n\nWhen it comes to supernutritious foods, the blueberry has long had a health halo floating over it.\nAnd when you eat a steady diet of them, they seem to have a number of positive health effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of strawberries and blueberries is not in question. But it does remind readers that if berries are not in season, frozen berries are still available and may have the same effect (if there is an effect).", "answer": 2}, {"article": "However, 37 percent showed only a minimal reduction of 9.6 percent in frequency of hot flashes, while 4 percent reported a 100 percent increase in hot flashes.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\n\u201cWomen will know pretty quickly if acupuncture will work for them.\nCo-authors include: Beverly Levine, Ph.D., Scott Isom, M.S., and Timothy Morgan, Ph.D., of Wake Forest Baptist; and Remy R. Coeytaux, M.D., Ph.D., of Duke University School of Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Acupuncture isn\u2019t a new idea, and many \u2014 if not most \u2014 readers would be familiar with the concept and aware of its availability. If this were a news story, we would like to see some discussion of how accessible acupuncture is. For example, one can be fairly certain of acupuncture practitioners being located in New York City. Whether one would be able to find certified practitioners in rural areas is less clear. However, we don\u2019t think that\u2019s an issue that needs to be addressed in a news release from a research hospital.", "answer": 1}, {"article": "\u201cBut it has hit the lay press,\u201d she said.\nThe small proof-of-principle study suggests a new way to inoculate babies, said Dr. Maria Gloria Dominguez-Bello, an associate professor of medicine at New York University and lead author of the report, published on Monday in Nature Medicine.\nDr. Dominguez-Bello and her colleagues then tracked the composition of microbes by taking more than 1,500 oral, skin and anal samples from the newborns, as well as vaginal samples from the mothers, over the first month after birth.\nCompared to infants who spent time squeezed inside the birth canal, those who were swabbed got less exposure to their mother\u2019s microbes.\nThe procedure is not yet recommended by professional medical societies, said Dr. Sara Brubaker, a specialist in maternal and fetal medicine at N.Y.U.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that this is not widely used among medical professionals but that women are sometimes doing it on their own or \u201carranging\u201d to have it done. Given the potential risks of colonizing a newborn with less than friendly bacteria, we think that the story\u2019s suggestion (and implicit encouragement) for women to do this on their own are unfortunate. \u00a0The study was intended to determine if newborns could be colonized artificially and not to study the effects in later life.", "answer": 1}, {"article": "In 2000, the UN Security Council convened an unprecedented meeting to address the out-of-control AIDS crisis.\nBut so far, the HIV community is carefully watching the Ad26 vaccine research because the approach seems quite promising.\nWe need more human studies of this HIV vaccine\n\nBut we still don\u2019t know if the vaccine will protect humans from the virus, since the studies so far have only looked at safety and immune responses, not efficacy.\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\nThe mosaic vaccine was the best tolerated and also capable of generating anti-HIV immune responses in all the people who received the shots.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear the vaccine is still in development and not likely to be available any time soon.", "answer": 1}, {"article": "The average age of the participants was 11.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\n\"We don't know the real effect of the cannabidiol, and we won't until we complete the studies that are ongoing that are placebo-controlled and blinded,\" added Brooks-Kayal, who is also a professor of pediatrics, neurology and pharmaceutical sciences at the University of Colorado School of Medicine.\nFamilies with adults and children with epilepsy have flocked to states where medical marijuana is legal to seek treatment, Brooks-Kayal said.\nCannabidiol is a major chemical component of marijuana, said Dr. Orrin Devinsky, a neurologist at NYU Langone Medical Center's Comprehensive Epilepsy Center in New York City and co-author of one of the studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One of the study investigators makes\u00a0it clear that federal approval for the drug could take up to five years.\u00a0 However, the story also notes that some activist families have already begun using cannabidiol oils \u201cthat are made artisanally.\u201d", "answer": 1}, {"article": "Patients with heart disease or who are using antidepressants known as selective serotonin reuptake inhibitors should also be careful when taking sumatriptans, said Waltman, who added that she thought the patches \"are wonderful.\"\nNuPathe Inc., which makes Zecuity, hopes to have the patch on the market later this year.\nNuPathe CEO Armando Anido told Bloomberg News, \"We anticipate the product will be available for sale in the fourth quarter of this year.\"\nAnother expert described the problem this way.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story estimates, from a company source, that this produce will be available toward the end of 2013.", "answer": 1}, {"article": "Patients with untreatable angina who received the injections of CD34+ stem cells in key areas of the heart had significantly fewer chest pain episodes and significantly better performance on exercise tests than patients who got placebo injections.\nThe stem cells have shown the ability to repair and replace them in animal models.\"\nThe approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\nResults from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\nThe newly reported study included 167 patients with severe angina treated at 26 medical centers across the country.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls the approach \u201cexperimental\u201d\u2026says Phase III studies are planned\u2026and ends with \u201cthe next step is to prove the treatment is clinicallly useful.\u201d", "answer": 1}, {"article": "The American Diabetes Association has more about diabetes-related eye complications.\nResults were similar after two years.\nThis is a \"seminal\" study,\" added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\n\"First and most importantly, it provides patients an improved therapy for diabetic macular edema.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never clarifies whether Lucentis is now approved and available. ", "answer": 0}, {"article": "MRI uses a powerful magnetic field and pulses of radiowave energy to create images.\nThe Cleveland Clinic has more on CT, MRI and similar tests.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\nBut doctors do not always want to run the risks that can be associated with that technique, and the leading candidates for less invasive assessment are CT and MRI.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that CT and MRI are currently used in clinical practice. Both techniques are routinely available for imaging of the heart in most academic and large community hospitals.", "answer": 1}, {"article": "In an analysis of 29 studies, they found people who got acupuncture typically reported more pain relief than those who didn\u2019t.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\nThat either means many of the three million Americans that get acupuncture every year are \u201cwasting their time\u201d - or others who forgo it are missing out on potential benefits, Vickers said.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\nBut, he added, \u201cI would sincerely say more than 75 percent of my patients will see improvement.\u201d\n\nVickers said people who are considering acupuncture should first make sure their acupuncturist is appropriately qualified and licensed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While acupuncture is mainstream enough to be available in\u00a0metropolitan areas, those living in rural places will often\u00a0have a tough time finding a licensed and qualified practitioner. Although the story could have been more emphatic on this point, it does\u00a0mention\u00a0the \u201cinconvenience of getting to a clinic\u201d as one of the main downsides of therapy. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nPatients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.\nThey were told to lie still with their eyes closed as they wore headphones and listened to soothing music.\nFederal law prohibits the use of the magic mushroom compound for any purpose.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Studies of large databases such as Medicare records or registries that enroll pregnant women already taking particular drugs are the chief ways to discover and measure possible risks to the fetus from prescription drugs.\nThat such an effect was first noticed a quarter-century after ACE inhibitors arrived on the market points up the lack of data about the effect of drugs in pregnancy.\nAll new drugs are tested on pregnant animals to see whether they cause malformations, but those tests can be misleading.\nAs a consequence, the labels on nearly all medications carry a statement saying their safety to fetuses has not been established.\nIt's considered unethical to include pregnant women in studies of new drugs unless the medication is intended to treat pregnancy-related conditions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that ACE inhibitors are a class of drugs available since the early 1980s; they are commonly prescribed.", "answer": 1}, {"article": "\u201cSome men go to the bathroom several times a night, get right back to sleep and are not bothered,\u201d he said.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\n\u201cThere is a big difference between having the symptoms and being bothered by the symptoms,\u201d said Dr. Kevin T. McVary, professor of urology at the Feinberg School of Medicine at Northwestern University.\nThat is because after age 50 many men face an embarrassing problem called B.P.H., for benign prostatic hyperplasia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story listed a number approaches to dealing with benign prostatic hyperplastia, including watchful waiting, medical therapy, minimally invasive procedures, surgery as well as experimental treatment involving botox. \u00a0The story was clear that the use of botox in this context is something under investigation and not something that is in current use. \u00a0The discussion of the other approaches indicated that they are available to men interested in treatment.", "answer": 1}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nWhen it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nThere are some limitations to mention about the new meta-analysis.\nBut even if later school start times only improve sleep time, that\u2019s a positive step for public health.\nDelaying school start times is easier said than done\n\nAs Vox\u2019s Libby Nelson has reported, very few schools have actually adopted this reform.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that\u00a0few schools have modified their start times in response to this issue. A\u00a0map is a great addition in this regard.", "answer": 1}, {"article": "For more information, visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nAvelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nUntil now, there were no systemic therapies approved by the Food and Drug Administration for this cancer, and no approved therapies once the cancer had spread.\nNewswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that this is the first therapy approved by the FDA for this particular type of cancer once it has spread.", "answer": 1}, {"article": "The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\nEarWell treatment was highly successful in correcting or reducing the severity of congenital ear malformations.\nThe ADRs are traded on the over-the-counter market in the U.S. (WTKWY).\nDr. Byrd comments, \"The EarWell system is effective in eliminating or reducing the need for surgery in all but the most severe congenital ear malformations.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the EarWell system is not new and is already in clinical use.", "answer": 1}, {"article": "\u201cOur next step will be to more precisely determine the underlying chemistry of how and why particular foods can yield dramatically different results for different people.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\nThat\u2019s the result of research by the University of Michigan Health System, presented at Digestive DiseaseWeek, that studied for the first time in the United States the result of following a carefully controlled diet to improve the symptoms and quality of life for those with irritable bowel syndrome.\nNewswise \u2014 A change in diet can improve the lives of those diagnosed with a common, but hard-to-treat gut disorder.\nThis diet excludes many compounds found in wheat, certain fruits and vegetables, garlic, onions and sugar substitutes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Information about the low FODMAP diet is widely available online.", "answer": 1}, {"article": "The studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\nThe studies related to this topic will be presented at the American Roentgen Ray Society annual meeting.\nIt recommended routine mammography screenings every two years for women ages 50 to 74.\nThe task force did not say don't get mammograms, Moyer said.\n\"I would still recommend screening mammograms starting at age of 40,\" because cancers caught earlier would be more curable.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of mammograms is not in question.", "answer": 2}, {"article": "Obstructive sleep apnea occurs when the soft tissues of the mouth and airway, especially the tongue, block air flow into the lungs.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nTurner would make little gasping sounds throughout the night.\nBut for Turner that\u2019s a small price to pay for a goodnight\u2019s sleep.\nThe doctors measured everything from brainwaves to breathing \u2014 what they found surprised Turner.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that the implantable pacemaker-like device was \u201capproved by the Food and Drug Administration in 2014.\u201d This is sufficient, but it\u00a0would have been helpful to know what types of doctors do the procedures and how widely it\u2019s offered.", "answer": 1}, {"article": "More than one million athletes experience a concussion each year in the United States.\n\"The potential of having an accessible technology that detects a physiological change following brain trauma is very exciting.\n\"While more research is needed, the hope is such a tool could one day be used on the sidelines to help determine more quickly whether an athlete needs further testing.\"\nTesting of the TCD technique at the sideline at the time of injury will be an important next step to determine its ultimate utility,\" said Randolph S. Marshall, MD, MS, with Columbia Presbyterian Medical Center in New York and a member of the American Academy of Neurology's Science Committee.\nBut those measurements haven't been enough to accurately detect concussion.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The second half of the news release discusses through comments of sources the need for further research to explore the utility of the device. That type of content sends the message\u00a0to readers that the technology is not yet available. We do have concerns with the language suggesting that this technology should be readily available at sporting events.", "answer": 1}, {"article": "RELATED: What we know about how cancer starts could all be wrong\n\nIn January 2013, nearly four months after Landon\u2019s initial diagnosis, the two went from Utah to Colorado, where Riddle purchased an alternative treatment fraught with complicated politics and plenty of skepticism\u2014especially when it comes to saving the life of a preschooler with a potentially fatal disease.\nShe decided to start Landon on cannabis.\nShe was willing to do whatever it took to keep him on cannabis.\nBut to do that, the family would need to leave Utah, where all cannabis is illegal.\n(Due to HIPAA patient privacy laws, Children\u2019s Hospital Colorado was unable to comment on Landon\u2019s case for this story.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story talks about the availability of marijuana in various states.", "answer": 1}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that supplements containing raspberry ketones are widely available.", "answer": 1}, {"article": ".\nBecause of the widespread resistance of bacteria to antibiotics on the market, there is an urgent need for the development of new antimicrobials.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\nTheir findings indicate that targeting SecA is an attractive antimicrobial strategy against MRSA and may be several times more effective than the antibiotics now available for treating the infection.\nThis study also confirmed that SecA inhibitors have the potential for being broad-spectrum antimicrobials, can directly block virulence factor production and can null the effect of efflux pumps.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Satisfactory, since we think most readers will come away understanding that there are no currently available treatments based on this approach. But the release doesn\u2019t explicitly establish the lack of availability of such treatments. Nor does it say how far we might be from having such treatments. Had there been some acknowledgment of the fact that this study was done in cell culture and not people, it would have been clearer that such treatments are not available and won\u2019t be any time soon.", "answer": 1}, {"article": "In spinal cord stimulation, a wire runs along the spinal cord sending pulses along the entire spine, but the pulses don't target the specific pain source.\nIt shows long-term data that patients experienced significant pain relief and functional improvements, she said.\nMcCarthy said the therapy is not widely available, even though it was approved by the FDA in 2016.\nFor most patients, the device reduced pain by 33 percent, which was significant, the researchers reported.\nOne pain specialist not involved with the study saw the benefits of this procedure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported that the device was approved by the FDA in 2016 and its use is confined to \u201cmore advanced medical centers where doctors have been trained in how to implant and regulate the device.\u201d\nAlso, it said the procedure \u201cisn\u2019t covered by all insurance companies, so out-of-pocket costs to patients can be very high,\u201d though it is covered by Medicare.", "answer": 1}, {"article": "This is when estrogen plummets, and estrogen helps protect bone health.\nWhen it comes to the most popular type of osteoporosis treatment, bisphosphonates, the question is not so much about how much to take, but whether there are harmful consequences from long-term use.\nAlso missing, Nelson said, are randomized studies that would indicate how often patients should be screened.\nHer task force recommended that an international registry be created for tracking such cases to help researchers better pinpoint which patients might be at risk.\nFor Dr. Douglas C. Bauer, a professor at the University of California-San Francisco and a researcher who also treats many osteoporosis patients, the hardest decision is when to stop the drugs in patients who still have low bone density after five years of treatment but are not especially frail.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All the screening, prevention, and treatment approaches described in this article are widely available and their availability doesn\u2019t merit extensive discussion.", "answer": 1}, {"article": "Varenicline contains no nicotine.\n\"The slower metabolizers, they do very well with the patch.\nResearchers did not test nicotine gum because it delivers a less consistent flow of nicotine to the user, she said.\nAbout 70 percent of smokers give up the daunting effort during the first week of trying.\nThe patch, worn on the skin, delivers a steady flow of the drug, she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The therapies in the story are widely available, but the patch is available over the counter and varenicline requires a prescription, which certainly impacts access. The story didn\u2019t mention this. In addition, the story doesn\u2019t describe the availability of the screening test that separates smokers into \u201cfast\u201d and \u201cslow\u201d metabolizers. We could not tell if that is easy for any primary care physician to order.", "answer": 0}, {"article": "Satisfactory relief was considered a 40 - 69 percent reduction in pain scores (6 patients) and excellent relief, pain reduction of 70 percent or more (5 patients).\nKobayashi believes neurologists would especially have an interest in this method, which is also attractive due to its low side-effect profile.\nIn 2014, a review[2] suggested that there is probable efficacy (a level A recommendation) for short-term rTMS treatment of neuropathic pain, including central post-stroke pain, but did not speak to long-term efficacy.\nHowever, Kobayashi and colleagues point out in their peer-reviewed online publication of this study, \u201cRepetitive Transcranial Magnetic Stimulation Once a Week Induces Sustainable Long-Term Relief of Central Poststroke Pain\u201d (Neuromodulation: Technology at the Neural Interface: April 23, 2015)[1] that there has still been controversy about the efficacy of rTMS in post-stroke pain.\nHe added that the remaining question to answer is whether the level of the patients\u2019 severe uncontrollable pain would continue to decrease if rTMS continued for several years.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "rTMS is commercially available and in widespread use in the US for the treatment of resistant depression. However, the release does not establish that fact, and few patients/consumers would be aware of it. A brief statement about the availability of the device and insurance coverage (none at the moment) would have been helpful for the average reader.", "answer": 0}, {"article": "Devices like the anti-gravity treadmill, enable walking or running without the full weight of the body so reducing the load on the joints in the lower limbs and bridging the gap between rehabilitation and return to sport.\nThe case report highlights the journey a 39-year-old female endurance runner took from the end of her post-knee surgery rehabilitation to taking part in her sport again.\nNews releases can also be found at http://www.\nThe team individually tailors rehabilitation programmes to support people in returning to sport and exercise activities after injury or surgery.\nThe cartilage covering the bone surface is not able to heal itself when it is damaged and this is why surgical procedures are available to repair the damaged area.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not tell us whether the device is available anywhere outside of the specific physical therapy facility profiled in the case study.", "answer": 0}, {"article": "No serious adverse events were reported.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nFevipiprant, which is being developed by Novartis, reduced a biological marker of asthma nearly five-fold in the 12-week trial involving 61 patients, researchers said on Saturday.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We believe the story attempts to give a realistic take, stating more study is needed to show that the drug can reduce severe asthma attacks. It also states Novartis \u201cbelieves the medicine could be filed for regulatory approval in around 2019.\u201d While this may or may not be accurate, it does let readers know that availability isn\u2019t around the corner.", "answer": 1}, {"article": "Collaborating with Dr. Pisco were Marisa Duarte, M.D., Tiago Bilhim, M.D., Ph.D., Jorge Branco, M.D., Ph.D., Fernando Cirurgi\u00e3o, M.D., Marcela Forjaz, M.D., L\u00facia Fernandes, M.D., Jos\u00e9 Pereira, M.D., Nuno Costa, M.D., Joana B. M. Pisco, M.D., and Ant\u00f3nio G. Oliveira, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://pubs. )\nPartial UFE may help reduce the risks of infertility associated with conventional UFE.\nDespite its less invasive nature, UFE has yet to be fully embraced in the medical community as a fertility-preserving treatment for women with symptomatic fibroids due to concerns that the procedure may cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries.\nDr. Pisco suggested that UFE may become the first-line treatment for women with fibroids who wish to conceive, particularly for those with numerous or very large fibroids.\n\"Our next step will be a randomized study comparing the results of partial and conventional UFE.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There is no explicit discussion of UFE\u2019s availability, but as conventional UFE is described as such, its availability is implicit.", "answer": 1}, {"article": "Every new podiatrist or orthopedist, he told me, would invariably look at his orthotics and say: \u201cOh, these aren\u2019t any good.\nThe only indication seems to be that a comfortable orthotic might be better than none at all, at least for the activities of people in the military.\n\u201cIf you do something to a shoe, different people will react differently.\u201d\n\nThe next problem is that there may be little agreement among orthotics makers about what sort of insert to prescribe.\n\u201cBut choosing the right one requires a great deal of care.\u201d\n\nYet Scott D. Cummings, president of the American Academy of Orthotists and Prosthetists, says the trade is only now moving toward becoming a science.\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both off-the-shelf and custom shoe inserts are widely available. This doesn\u2019t merit discussion.", "answer": 1}, {"article": "Andersson will present the study, \"Association Between Erectile Dysfunction and Death or Cardiovascular Outcomes After Myocardial Infarction,\" on Friday, March 17, at 1:30 p.m.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\n\"This type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death.\"\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\n\"From the perspective of a doctor, if a patient asks about erectile dysfunction drugs after a heart attack and has no contraindications for PDE5 inhibitors, based on these results you can feel safe about prescribing it.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the research was retrospective, it is clear that drugs used to treat ED are available and have been for some time.", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\nThe children were given food and drinks totaling the same number of calories, fat, protein and carbohydrates as their typical diets.\nThis lowered dietary sugar from 28 percent to 10 percent, and fructose from 12 percent to 4 percent of total calories.\n\u201cWithout changing total carbohydrate, or fat, or protein, we were able to accomplish this enormous improvement in their cardiovascular risk factors,\u201d unrelated to weight loss, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Bagels and pizza are ubiquitous.", "answer": 1}, {"article": "Sacroiliac joint dysfunction is a common cause of disabling pain in the lower back, buttocks, or groin.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\nThe minimally invasive SIJ implant approach evaluated in this trial has been cleared by the US Food and Drug Administration.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Because the study involved 19 U.S. sites we know there are a number of medical institutions capable of performing the implant. In addition, the release states that the procedure is FDA approved.", "answer": 1}, {"article": "Statin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\nNOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\n(March 23, 2017)\u2014Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty obvious that statins are everywhere in America.", "answer": 2}, {"article": "Researchers compared death rates from breast cancer among four groups of women: two that were living in counties with or without screening and two groups that lived in the same counties before screening was offered.\nMaybe Not and Here's Why, suggested that with better treatment and increased awareness of the importance of seeking care for breast abnormalities, screening mammography may be less important now than in the past.\n\"Mammography is not perfect; no one has claimed that it is,\" said Kopans, a member of the ACR Commission on Breast Imaging.\nFor the study, more than 40,000 Norwegian women were followed for an average of 2.2 years.\nThey both said that the time frame was insufficient to assess the effect of screening.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of mammograms is clear from the story. ", "answer": 1}, {"article": "Trachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.\nThis is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.\nCo-author and McMaster PhD student, Steven Liang, explains, \"not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.\"\n\"Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.\"\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes no mention of the fact that this vaccine is very far away from a clinical application, assuming it would even pass human trials. Instead, it talks about how easy the vaccine would be to administer and how people wouldn\u2019t even need a lot of training to administer it.\n(We imagine that administering nasal doses to mice would require some training.)", "answer": 0}, {"article": "Traditionally, dentists were taught that the only way to deal with decay was to drill it out.\nWhen Featherstone put his patients on personal treatment plans, he found the strategy worked.\nIf the high-pitched whir of a dentist's drill as it bores into your molar terrifies you, good news!\nAnd he expects that at some point all dentists will follow a preventive protocol.\nBut cost has been an issue.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the treatments mentioned in the story are widely available, and we were pleased to see the story went a step further and let us know how insurance impacts availability.\n\u00a0", "answer": 1}, {"article": "\u2022 Measure baseline omega-3 intake or status of study participants to determine the extent to which it confounds results.\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\nThe study was supported by a grant from GOED, which played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.\nAn accompanying editorial in Mayo Clinic Proceedings also acknowledges the importance of the study.\n\"What makes this paper unique is that it looked at the effects of EPA and DHA on coronary heart disease specifically, which is an important nuance considering coronary heart disease accounts for half of all cardiovascular deaths in the U.S.,\" said Dr. Dominik Alexander, lead author and Principal Epidemiologist for EpidStat.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release refers to consuming EPA and DHA in the form of either seafood or supplements, so we\u2019ll give this a pass. However, that single reference to sources of EPA and DHA is only found in a quote in the tenth paragraph.", "answer": 1}, {"article": "Merck suffered a setback last year when its attempts to win marketing approval to sell Erbitux in lung cancer were rebuffed by regulators.\n\u201cThis study clearly opens the field ...\nSales last year were $1.7 billion.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "A biopsy involves the removal of tissue or fluids to test for disease.\nTUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\nIn addition, image-guided biopsies are more accurate, Quencer said.\nThe report is published online and in the September print edition of Radiology.\nThat's an annual growth of 3 percent in number of biopsies, the researchers noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability \u2013 and growing use of \u2013 less invasive biopsies is the whole point of the story. But the story didn\u2019t clarify how broad the study sample was \u2013 and how representative of different health care settings large and small, urban and rural, etc.. For this information to be truly meaningful and helpful to readers all over the US, such scrutiny is vital. ", "answer": 0}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\nThe drug is not regularly given to patients with Type 1 diabetes.\nMetformin may be used to lower Type 1 diabetic patients' risk of developing this complication.\nMetformin is an inexpensive treatment that is often used for Type 2 diabetes to lower blood sugar levels by reducing glucose production in the liver.\nFindings of the clinical trial are published today in the journal, Cardiovascular Diabetology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since metformin is readily available and currently used in treating type 2 diabetes, the release gets a satisfactory rating in this category.", "answer": 1}, {"article": "Sept. 26, 2017.\nBut we continue to prescribe it because it is highly effective, reversible and inexpensive.\nDespite its longtime use, warfarin remains tricky to dose because a person's genetic makeup influences how the drug is processed in the body.\nNow, a new study led by Washington University School of Medicine in St. Louis shows that dosing warfarin (Coumadin and others) is safer -- producing fewer adverse events such as hemorrhage -- when key elements of a patient's genetic makeup are considered.\n\"It's a widely used anticoagulant, but it causes more major adverse events than any other oral drug.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The careful reader will get it: testing for these genetic variants is still an experimental practice for the most part, and further testing of how the mutations affect warfarin is needed. But the release could have been more explicit in saying that no one is yet recommending genetic testing for millions of warfarin users.\nWhile the genetic tests are \u201cavailable\u201d in the sense that anyone can order them for the most part, they are not routinely used clinically and probably wouldn\u2019t be covered by insurance so in that sense they are not widely available to most people. ", "answer": 0}, {"article": "The disease is characterized by an itching, oozing rash that can cover almost all of the skin.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nThere has never been a safe and effective treatment.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\nNearly 40 percent of participants getting the drug saw all or almost all of their rash disappear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the companies are seeking FDA approval of dupilumab and that the agency has given the drug \u201cbreakthrough\u201d status, which allows for expedited development and review. It would have been helpful if the story had acknowledged that this doesn\u2019t necessarily mean \u201cbreakthrough\u201d in the way many people understand the word.", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that the drug ustekinumab is an experimental drug still being studied. ", "answer": 1}, {"article": "\"It's not far-fetched that the pharmaceutical industry will try to create a supplement of these microbiomes, much like was done with probiotics,\" she said.\nA new University of Alberta study showed that babies from families with pets--70 per cent of which were dogs--showed higher levels of two types of microbes associated with lower risks of allergic disease and obesity.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\nIf you need a reason to become a dog lover, how about their ability to help protect kids from allergies and obesity?\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that the availability of dogs in the US is a fact that doesn\u2019t even need to be mentioned. According to the ASPCA, 44% of American households have a dog.", "answer": 2}, {"article": "More than 70,000 people in the United States and 160,000 worldwide are diagnosed with melanoma each year, according to the American Cancer Society.\nShe and others expect vemurafenib to be approved this year.\nBristol-Myers\u2019 Yervoy was approved in March for patients with inoperable or metastatic melanoma, based on a previous study which showed the drug given alone extended survival by four months in patients who had failed other treatments.\n\u201cThat is a drug that can take a while to work, so if the person has time I would rather give him essentially two shots on goal rather than one.\u201d\n\nFor advanced patients who need a quick response, he would use vemurafenib first.\nThe five-year survival rate for the aggressive cancer is just 15 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Adequately described. The story appropriately notes that vemurafenib is experimental and Yervoy has been approved for use in the US.", "answer": 1}, {"article": "When patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\nTo assess the cost-effectiveness of the device versus medication, the researchers developed a statistical model based on data from two key research trials, known as PROTECT AF and PREVAIL.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not say that the FDA approved the device last year, or how widely available it is.", "answer": 0}, {"article": "It takes an hour or less,\" he said.\nAnd not every failure is deadly.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\nAll the patients had devices that were recalled by manufacturers, Canada's national health system or the FDA.\nTwo patients died.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the article that defibrillators are available.", "answer": 1}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine.\nOffering the full portfolio of business education courses, from undergraduate through to MBAs, and with a strong Doctoral Programme, WBS is the complete business school.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\nFor a copy of the paper email Ashley.potter@wbs.ac.uk\n\nWarwick Business School is the largest department of the University of Warwick and is triple accredited by the leading global business education associations - the first in the UK to attain this accreditation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that modafinil is already on the market and widely available around the world.", "answer": 1}, {"article": "Flublok is an exact copy of the influenza virus coat protein and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al.\nFlublok Quadrivalent was approved by the FDA in October 2016 and will be available nationwide in prefilled syringes for the upcoming flu season.\nFDA approved the quadrivalent formulation (\"Flublok Quadrivalent\") in October 2016 that will be commercially available for everyone over 18 years for the 2017/18 influenza season.\nFlublok Quadrivalent is FDA approved for adults 18 and older.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release explicitly states that: \u201cFlublok Quadrivalent was approved by the FDA in October 2016 and will be available nationwide in prefilled syringes for the upcoming flu season.\u201d", "answer": 1}, {"article": "\u201cI think that\u2019s important because it paves the way for potentially studying patients without chronic pain and offering the treatment sometime in the future to reduce blood pressure,\u201d he says.\nPatel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\nThe case study is published in the Jan. 25 issue of Neurology.\nPereira wrote about blood pressure reductions in a patient getting deep brain stimulation in the January 2010 issue of the Journal of Clinical Neuroscience.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that we are not close to seeing\u00a0DBS used to\u00a0treat hypertension outside of a research setting. Unlike the competing HealthDay coverage, the story notes that DBS is FDA approved for Parkinson\u2019s disease and essential tremor, and that it is used for other conditions. We would have liked to have seen at least an expert view on the number of devices that are implanted every year or a statistic on this\u00a0from one of the manufacturers.", "answer": 1}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that both GeneSight from Myriad Genetics, and Genecept from Genomind, are commercially available.", "answer": 1}, {"article": "SpermCheck Fertility is designed to help couples determine more quickly whether male infertility might be a problem for them, said Ray Lopez, CEO of SpermCheck, based in Charlottesville, Va.\nThis test, which is noninvasive, could be wake-up call for some.\nAfter about 11 months of trying, she had pushed her husband to get a semen analysis from a doctor.\n\"It was blatantly negative.\nScott said she was surprised by the number of steps involved, although none were very difficult.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the test is new to the market but now available in retail stores.", "answer": 1}]